WO1999002956A2 - Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) - Google Patents
Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) Download PDFInfo
- Publication number
- WO1999002956A2 WO1999002956A2 PCT/US1998/011937 US9811937W WO9902956A2 WO 1999002956 A2 WO1999002956 A2 WO 1999002956A2 US 9811937 W US9811937 W US 9811937W WO 9902956 A2 WO9902956 A2 WO 9902956A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- radiation
- return
- modulated
- sensor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 238000004611 spectroscopical analysis Methods 0.000 title claims abstract description 11
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 title abstract description 22
- 230000005855 radiation Effects 0.000 claims abstract description 121
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 54
- 238000012544 monitoring process Methods 0.000 claims abstract description 22
- 230000008569 process Effects 0.000 claims abstract description 13
- 239000000523 sample Substances 0.000 claims description 233
- 239000013307 optical fiber Substances 0.000 claims description 43
- 230000003287 optical effect Effects 0.000 claims description 40
- 230000005284 excitation Effects 0.000 claims description 35
- 208000028867 ischemia Diseases 0.000 claims description 32
- 230000007954 hypoxia Effects 0.000 claims description 28
- 108010054147 Hemoglobins Proteins 0.000 claims description 23
- 102000001554 Hemoglobins Human genes 0.000 claims description 23
- 238000010521 absorption reaction Methods 0.000 claims description 20
- 238000006213 oxygenation reaction Methods 0.000 claims description 12
- 230000001766 physiological effect Effects 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 238000002834 transmittance Methods 0.000 claims description 11
- 230000001575 pathological effect Effects 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000015654 memory Effects 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000000287 tissue oxygenation Effects 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims 22
- 230000001678 irradiating effect Effects 0.000 claims 7
- 238000002189 fluorescence spectrum Methods 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 abstract description 34
- 230000001419 dependent effect Effects 0.000 abstract description 32
- 230000001146 hypoxic effect Effects 0.000 abstract description 21
- 210000001519 tissue Anatomy 0.000 description 127
- 238000001228 spectrum Methods 0.000 description 57
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 24
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 230000003595 spectral effect Effects 0.000 description 19
- 239000000835 fiber Substances 0.000 description 18
- 230000036982 action potential Effects 0.000 description 15
- 230000008602 contraction Effects 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 8
- 108010014258 Elastin Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 229920002549 elastin Polymers 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 238000013528 artificial neural network Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000010287 polarization Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000011149 active material Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000005350 fused silica glass Substances 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000000222 hyperoxic effect Effects 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010238 partial least squares regression Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012306 spectroscopic technique Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UIZLQMLDSWKZGC-UHFFFAOYSA-N cadmium helium Chemical compound [He].[Cd] UIZLQMLDSWKZGC-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000014541 detection of hypoxia Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012799 electrically-conductive coating Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012770 industrial material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N2021/6484—Optical fibres
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/061—Sources
- G01N2201/06193—Secundary in-situ sources, e.g. fluorescent particles
Definitions
- the present invention is directed to methods and devices for determining a spectroscopic characteristic of a sample utilizing laser induced fluorescence attenuation spectroscopy ("LIFAS"). More particularly, the invention is directed to methods and devices for measurement of the wavelength-dependent attenuation of the sample and subsequent restoration of the intrinsic laser induced fluorescence (“LIF”) for phsyioloical monitoring, biological tissue characterization and biochemical analysis.
- LIFAS laser induced fluorescence attenuation spectroscopy
- samples have been characterized by determining the attenuation and laser induced fluorescence ("LIF") .
- LIF laser induced fluorescence
- these spectroscopic properties can be utilized to determine a physical or physiological property of the sample .
- the attenuation of a sample can be used to determine the concentration of a mixture components or turbidity of a fluid.
- the LIF of a sample has been used in fields such as analytical chemistry, environmental monitoring, industrial inspection and medical diagnosis. In the medical field, for example, LIF spectroscopic techniques have been used for tissue characterization, malignant tumor identification, atherosclerotic plaque diagnosis, metabolism evaluation, and the like.
- the attenuation or the absorption of a sample is determined by placing the sample between a light source and a detector and measuring any reduction in the intensity of the light as it passes through the sample .
- the thickness of the sample and the wavelength of the incident light are important factors affecting the reliability of the resulting measurement.
- it is necessary to place the sample between the light source and the detector it is difficult to perform attenuation measurements on certain types of samples, such as living tissue.
- fiber optic techniques have been developed for the measurement of attenuation in which an optical fiber is used to guide the incident light to illuminate a sample inside a small chamber at the tip of a probe.
- a reflector is placed on the opposite side of the chamber to reflect the incident light into a second fiber which is associated with a detector.
- these techniques find limited application with materials, such as fluids, that can readily pass into the chamber in the tip of the probe .
- LIFS laser induced fluorescence
- spectroscopic techniques utilize various optical configurations in which a laser is directed at a sample using an optical fiber and the LIF from the sample is collected using a second optical fiber.
- the same fiber can be used for excitation of the sample and the collection of LIF.
- the LIF collected by the fiber is modulated by the sample, e.g. by the wavelength-dependent absorption and scattering of constituents of the sample. Therefore, existing LIFS methods are limited by the fact that the "intrinsic" or "true” fluorescence of the sample's fluorophores cannot be determined.
- Recent reports have suggested measuring the diffuse reflectance spectrum of the tissue as a means for correcting the intrinsic LIF using Monte-Carlo mathematical formulations.
- the tissue is deprived of oxygen and anaerobic respiration takes place. Consequently, the weak fluorophore NAD will be converted into the strong fluorophore reduced nicotinamide adenine dinucleotide ("NADH") .
- NADH nicotinamide adenine dinucleotide
- the LIF collected from the sample will reflect an increased contribution from NADH. This change is typically observed as a rise in the intensity of the LIF spectrum in the region of peak NADH emission, from about 470 to 490 nm.
- the metabolic state of the tissue can be determined by measuring the relative change in LIF intensity at the wavelength of peak NADH emission as compared to the relative change of the LIF intensity of fluorophores that are normally present in the tissue, such as elastin or collagen.
- the LIF of biological tissue is heavily modulated in the 390-450 nm range by the peak absorption of the main tissue chromophore, hemoglobin.
- the measured LIF spectra has a valley in the 400-450 nm region that is associated with the hemoglobin absorption.
- the measured LIF spectrum tissue appears to have a double peak instead of the single peak spectrum associated with the pure fluorophores of the tissue.
- the LIF spectrum of normal tissue begins to resemble the spectrum associated with tissue suffering hypoxia or ischemia, which makes it more difficult to identify tissue abnormalities .
- Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event .
- ischemic or hypoxic event Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event .
- ischemia i.e., ischemia
- continuous monitoring of the organ is typically required.
- Ischemia and hypoxia are both conditions that deprive tissue of oxygen, leading to anaerobic metabolism and the accumulation of the metabolic coenzyme NADH.
- the coenzyme NADH is a fluorescent molecule. Therefore, ischemia and hypoxia can be indirectly detected using LIF techniques by sensing increased concentrations of NADH and interpreting its elevation as a sign of oxygen deficiency.
- a common indicator of oxygen deficiency is the ratio between the LIF intensity at wavelengths associated with the peak fluorescence emission of NADH, collagen and elastin.
- such methods have not been practically applied for the detection of ischemia because of several complications. First, these methods cannot determine whether the elevated NADH concentration is caused by ischemia, hypoxia or hypermetabolism.
- the indicator ratios are calculated by normalizing the intensity of NADH peak fluorescence by that of collagen or elastin. Although the fluorescence of the structural proteins elastin and collagen does not vary with tissue oxygenation, the fluorescence with the site of measurement.
- the intrinsic LIF of biological tissue have a single peak spectral profile resembling that of the pure structural proteins which are primarily elastin and collagen.
- this single peak profile is modulated by the attenuation of hemoglobin, especially about 410 nm, to yield a distorted, double-peak spectrum.
- the second spurious peak at about 470 nm results from the spectral valley created by heavy hemoglobin absorption at about 410 nm.
- this second peak overlaps and obscures the peak fluorescence emission of NADH at about 470- 490 nm, which may impede ischemia detection techniques that are based on NADH concentration.
- the methods and devices of the present invention will enable measurement of several LIF parameters that directly relate to the state of tissue perfusion and/or hemoglobin oxygenation. This offer superior accuracy over the currently available LIF techniques which detect ischemia and hypoxia indirectly by sensing an upsurge in NADH fluorescence.
- the methods and devices of the present invention can directly indicate the presence and the level of hypoxia or ischemia.
- the methods of the present invention utilize novel criteria for discrimination between normal and ischemic or hypoxic tissue.
- the present invention is embodied in a system and related method for laser induced fluorescence attenuation spectroscopy ("LIFAS") in which the attenuation and intrinsic LIF of a sample can be determined.
- the LIFAS system employs a source, a first sensor, a second sensor and a processor.
- the source preferably a laser, emits light to irradiate a sample volume in a sample so that the sample volume produces return light, which preferably includes laser induced fluorescence.
- the first sensor monitors the return light at a first distance from the sample volume and generates a plurality of signals representing the intensity of the return light in predetermined wavelength bands .
- the second sensor monitors the return light at a second distance from the sample volume and generates a plurality of signals representing the intensity of the return light, preferably over the same wavelength bands.
- the processor can be used to determine the wavelength-dependent attenuation of the sample using the signals of both sensors.
- the measured attenuation will typically reflect the effects of both absorption and scattering by the sample.
- the first and second detectors monitor return light from the sample volume at a location in proximity to the sample volume .
- the attenuation can be used to restore the intrinsic LIF of the fluorophores of the sample. Once the attenuation and intrinsic fluorescence have been determined, these factors can be used in a variety of applications, including medical diagnosis.
- the attenuation and fluorescence are used for the detection of ischemia and hypoxia of biological tissue. Ischemia and hypoxia are detected by monitoring spectral changes in the intrinsic LIF to detect a rise in the concentration of NADH in the tissue. Since ischemia is caused by a decrease in the blood content of the tissue, ischemic tissue will have lower concentrations of hemoglobin.
- MAM can be used as an attenuation or fluorescence spectral classifier.
- FIG. 1 is a schematic diagram of a spectroscopic system in accordance with the invention
- FIG. 2 is a schematic diagram of a Laser Induced Fluorescence Attenuation Spectroscopy system ("LIFAS") in accordance with the present invention having an excitation waveguide and a first and second collection waveguides;
- FIG. 3 is a schematic diagram of a LIFAS system in accordance with the present invention having a first excitation-collection waveguide and a second collection only waveguide;
- FIG. 4 is schematic diagram of a LIFAS system for biomedical applications in which excitation radiation is used to induce fluorescence of tissue;
- LIFAS Laser Induced Fluorescence Attenuation Spectroscopy system
- FIGS. 5(a) and (b) are end perspective views of a LIFAS probe having an optical fiber and an optical fiber bundle as the central waveguide ;
- FIGS. 6(a) and (b) are partial perspective views of an electrical subsystem used to synchronize a LIFAS system with the electrical activity of tissue using electrodes integrated into the optical probe;
- FIGS. 7(a) and (b) are schematic diagrams showing the relative positions of the action potential and electrodes integrated into the optical probe; and FIGS. 7(c) and (d) are the corresponding action potential timing diagrams;
- FIG. 8 is a perspective view of a probe incorporating a visible light source for probe positioning and a circular LED array for indicating the direction of contraction propagation;
- FIGS. 9 (a) -(c) are partial perspective views of three LIFAS probes having waveguides arranged in different geometrical configurations adapted for different applications;
- FIG. 10 is a schematic diagram of a biomedical LIFAS system in accordance with the invention in which a single optical detector is used to measure the return light from two collection fibers;
- FIG. 11 is a block diagram of the method for determining the attenuation and the intrinsic fluorescence of a sample;
- FIG. 12 is a graph of the attenuation spectrum measured from normal and ischemic renal cortex of rabbit kidney using LIFAS devices and methods in accordance with the invention
- FIG. 13 is a scatter plot of the fluorescence intensity at 480 nm acquired from hypoxic (+) , normal (o) and hyperoxic (x) tissue through excitation-collection and collection-only waveguides;
- FIG. 14 is a graph of the intensity I co ( ⁇ ) c of the signal measured by a collection-only waveguide from normal, hyperoxic and hypoxic tissue;
- FIG. 15(a) is a graph of the modulated LIF spectra of normal and ischemic kidney, and
- FIG. 15(b) is a graph of the intrinsic LIF spectra of normal and ischemic kidney;
- FIGS. 16(a) and (b) are graphs of typical modulated LIF spectra of normal and ischemic kidney, respectively, depicting the difference in the symmetry of the main lobe;
- FIGS. 17 (a) -(b) are graphs of the mean LIF intensity of live kidney and heart tissue and FIGS. 17 (c) - (d) are the corresponding LIFAS-derived attenuation spectra.
- the present invention is embodied in a spectroscopic system 110 and related method for measuring the attenuation and/or optical rotation caused by a sample 114.
- the spectroscopic system 110 shown in FIG. 1 includes a source 111 that produces radiation 112, which is directed at a sample volume 113 within the sample 114.
- the source 111 is preferably a laser and the radiation 112 is preferably monochromatic ultraviolet (UV) , visible or infrared (IR) radiation 112. Nevertheless, the source 111 can be selected to produce other types of radiation, such as broad-band or polarized radiation, useful for a particular application.
- UV monochromatic ultraviolet
- IR infrared
- the spectroscopic system 110 further includes a first sensor 116 displaced by a distance Zl from the sample volume 113, and a second sensor 118 displaced by a distance Z2 from the sample volume 113, which are used to monitor return radiation 120 from the sample 114.
- the return radiation 120 will include fluorescence of the flurophores of the sample 114.
- the sensors 116 and 118 each include an aperature 116a and 118a, respectively, through which the return radiation 120 is observed and collected.
- the sensors 116 and 118 typically can only observe the events occurring within the volume defined by a solid angle emerging from the aperture of the sensor. This volume is known as the numerical aperture or the field of view of the sensor.
- first and second sensors 116 and 118 include numerical apertures 117 and 119, respectively, that are adapted to receive a portion of the return radiation 120 from the sample 114.
- the sensors 116 and 118 can be tilted at different angles ⁇ x and ⁇ 2 and selected to have different numerical apertures 117 and 119 so that the sensors 116 and 118 can selectively monitor return radiation 120 from all or part of the sample volume 113.
- the sensors 116 and 118 each generate a signal 124a and 125a, respectively, representing the intensity I cl ( ⁇ ) and I c2 ( ⁇ ) and/or polarization of the return radiation 120.
- the signals 124a and 125a are generated at a plurality of wavelengths within predetermined wavelength bands.
- the signal 124a from the first sensor 116 and the signal 125a from the second sensor 118 are communicated by signal paths 124 and 125, respectively, to a processor 123.
- the processor 123 processes the signals 124a and 125a to determine a spectral characteristic of interest, such as the attenuation and/or optical rotation of the return radiation 120 caused by the sample 114.
- the sensors 116 and 118 are positioned at non-equivalent distances Zl and Z2 from the sample volume 113.
- the first and second sensors 116 and 118 will be positioned so that one of the sensors will be in the immediate proximity of the sample volume 113 while the other sensor is positioned at a location adjacent to the first sensor, but displaced slightly further from the sample volume 113. It has been found that this arrangement advantageously improves the signal-to-noise ratio and, hence, measurement accuracy of the spectroscopic system 110.
- the attenuation of the return radiation 120 is dependent on the distance traveled by the return radiation 120 through the sample 114.
- the signal 124a measured by the first sensor 116 and the signal 125a measured by the second sensor 118 will suffer different attenuation where the distances Zl and Z2 from the sample volume 113 are not equivalent.
- the processor 123 can be used to process the signals 124a and 125a to determine the wavelength-dependent attenuation of the sample 114.
- the attenuation determined by the spectroscopic system 110 will reflect the effects of light absorption and scattering by the sample 114.
- the attenuation of the sample 114 can be used to determine the intrinsic fluorescence 129 of the fluorophores in the sample volume 113. The methods by which the attenuation and intrinsic LIF are determined are discussed in detail below.
- the source 111 can be any radiation source, such as a laser or a lamp emitting excitation radiation 112 at a wavelength capable of interacting with the sample 114.
- the sensors 116 and 118 will preferably include a detector, which can be as simple as individual light-sensitive diodes with appropriate band pass filters, or more complicated sensors such as an optical spectrum analyzer.
- the sensor is a suitable spectrograph or spectrometer equipped with a suitable sensor.
- the sensor can include a multispectral CCD camera.
- the source 111 is an XeCl excimer laser emitting monochromatic ultraviolet radiation at 308 nm.
- Each of the sensors 116 and 118 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum.
- PDA 1024 element intensified photo diode array
- Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) .
- OMA optical multichannel analyzer
- the OMA reads the light spectrum imaged by the PDA to produce the signals 124a and 125a.
- a 335 nm longpass filter (Schott WG335) is placed in front of the aperture of each of the sensors 116 and 118 to remove any backscattered 308 nm excitation radiation.
- the processor 123 is a personal computer that is networked to each of the sensors 116 and 118 via the signal paths 124 and 125 to receive the signals 124a and 125a, respectively.
- optical rotation is observed in optically active materials.
- An optically active material is characterized by a lack of symmetry in its molecular or crystalline structure which causes a rotation of the plane of polarization in incident-plane-polarized radiation.
- the extent to which the plane of polarization is rotated will typically vary from one optically active material to another.
- the extent of rotation may depend on the number of molecules in the path of the radiation, the wavelength of the radiation, and the temperature of the material.
- Anisotrophy is caused by a selective response of the sample to radiation travelling in different directions.
- anisotrophy can result from microscopic inhomogenetics in the tissue structure.
- Use of equivalent distances Zl and Z2 will minimize the contribution of the path- length-dependent attenuation to the overall attenuation measured by the system 110. Therefore, the optical rotation or anisotropy of the sample can be determined more easily.
- the LIFA system 110 shown in FIG. 1 can be adapted to measure optical rotation by utilizing first and second sensors 116 and 118 which are adapted to measure the polarization-dependent intensity of the return radiation.
- the first sensor 116 can be adapted to measure a first optical angle ⁇ x yielding the maximum intensity of the first portion 128 of the return radiation 120.
- the second sensor 118 can be adapted to measure a second optical angle ⁇ 2 yielding the maximum intensity of the second portion 130 of the return light.
- the optical rotation of the return light 120 will be given by the difference between the angles ⁇ x and ⁇ 2 , provided that the system has been properly calibrated.
- the same sensor is used for determination of the attenuation of the sample will find utility for monitoring the optical rotation.
- These sensors can be adapted to such measurements by placing a rotatable polarizing filter at each of the apertures 116a and 118a of the first and second sensors 116 and 118, respectively.
- FIG. 2(a) An alternative embodiment of the present invention is shown in FIG. 2(a) .
- the spectroscopic system 110 of FIG. 1 has been adapted as a Laser Induced Fluorescence Attenuation Spectroscopy ("LIFAS") system 210.
- LIFAS Laser Induced Fluorescence Attenuation Spectroscopy
- a source 211 emits laser radiation 212 at an intensity and a wavelength capable of inducing fluorescence of the sample 214.
- the laser radiation 212 is transmitted through an excitation waveguide 215 to a sample volume 213 within the sample 214 where the laser radiation 212 excites local fluorophores in the sample volume 213 to emit intrinsic fluorescence 229.
- the intrinsic fluorescence 229 of the fluorophores in the sample volume 213 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) present in the sample 214, respectively.
- Two collection waveguides 221 and 222 having apertures 221a and 222a and numerical aperatures 217 and 219 are disposed about the excitation waveguide 215.
- the collection waveguides 221 and 222 may be positioned such that their apertures 221a and 222b are laterally displaced from the excitation waveguide 215 by the distances xl ' and x2 ' and/or axially displaced from the aperture 215a of the excitation waveguide 215 by the distances yl ' and y2 ' .
- the lateral distances xl ' and x2 ' are small or zero.
- the axial distances yl ' and y2 ' are preferably selected to be small and unequal, while one of the axial distances is preferably zero. Also, it is desirable to position the apertures 215a, 221a and 222a of the waveguides 215, 221 and 222 in close proximity to or in contact with the sample 214 during use of the LIFAS system 210, as shown in FIG. 2(a) .
- FIG. 2(c) An alternative configuration of the collection waveguides is shown in FIG. 2(c).
- the axial distances yl ' and y2 ' are both zero.
- the lateral distances xl ' and x2 ' are selected to be small and unequal.
- the apertures 240a and 242a of the waveguides 240 and 242 are oblique such that the fields of view 244 and 246 are directed toward the sample volume 213 and to advantageously encompass the bulk of the sample volume 213. As shown in FIG.
- the distances zl' and z2 ' are directed along the respective axes of the numerical aperatures 244 and 246 and extend from the surface of the apertures 240a and 242a to the point of intersection of the axes of the numerical aperatures 244 and 246, respectively.
- the collection waveguide 221 collects a first portion 228 of the return light 220 and transmits the first portion 228 of the return light 220 to a first sensor 216.
- the first sensor 216 generates a first signal 224a, representing the intensity I cl ( ⁇ ) of the first portion 228 of the return light 220 at a plurality of wavelengths within predetermined wavelength bands.
- the collection waveguide 222 collects a second portion 230 of the return light 220 and transmits the second portion 230 of the return light 220 to the second sensor 218.
- the second sensor 218 generates a second signal 225a representing the intensity I c2 ( ⁇ ) of the second portion 230 of the return light 220 at a plurality of wavelengths preferably within the same wavelengths bands monitored by the first sensor 216.
- the processor 223 then processes the first and second signals 224a and 225a to determine the wavelength-dependent attenuation of the sample 214. As discussed in detail, below, once the attenuation is known, either of the signals 224a or 225a can be processed to minimize the effects of attenuation and determine the intrinsic LIF 229 of the fluorophores in the sample volume 213. Alternatively, if the sensors 216 and 218 are selected to monitor the polarization of the first portion 228 and the second portion 230 of the return light 220, the processor 223 can be used to determine the optical rotation of the return light 220 caused by the sample 214.
- the intensity and wavelength of the laser radiation 212 should be sufficient to create a sample volume 213 that is large enough to have some overlap with the numerical apertures 217 and 219 of the collection waveguides 221 and 222, respectively.
- the numerical apertures 217 and 219 can be selected to encompass all or parts of the sample volume 213.
- longpass filters are placed before the inputs of the sensors 216 and 218 to selectively block backscattered excitation radiation.
- the source 211 is an Xe-Cl excimer laser emitting 308 nm ultraviolet excitation radiation 212.
- the waveguides 215, 221 and 222 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability.
- the optical bundle and fibers are made of fused silica which is transparent to ultraviolet radiation.
- a 1.4 mm diameter optical bundle is used as the excitation waveguide 215 while the collection waveguides 221 and 222 are 0.4 mm optical fibers disposed about the excitation bundle.
- the lateral range xl ' and x2 ' are equal to zero while the axial distance yl ' is about 0.6 mm and the axial distance y2 ' is about zero.
- the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
- each of the sensors 216 and 218 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) .
- PDA 1024 element intensified photo diode array
- Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) which measures the intensity of the light spectrum imaged by the PDA and produces the signals 224a and 225a.
- OMA III optical multichannel analyzer
- the processor 223 is a personal computer that is networked to each of the sensors 216 and 218 via the signal paths 224 and 225 to receive the signals 224a and 225a, respectively.
- FIG. 11 illustrates the main steps involved in determining the wavelength-dependent attenuation coefficient ⁇ ( ⁇ ) and the intrinsic fluorescence I ⁇ ( ⁇ ) of a sample in accordance with the current invention.
- the first and second portions 228 and 230 of the return light 220 experience different attenuation effects due to the unequal path lengths traversed by the return light 220 from the sample volume 213 to the apertures 221a and 222a of the collection waveguides 221 and 222.
- the first portion 228 of the return light 220 collected by the aperture 221a travels an additional path-length of ⁇ yl'-y2' ⁇ through the tissue as compared to the second portion 230 of the return light 220 which is collected by the aperture 222a.
- the first portion 228 of the return light 220 suffers more path-length-dependent attenuation as compared to the second portion 230 of the return light 220.
- the signals 224a and 225a representing the intensity I cl ( ⁇ ) and I c2 ( ⁇ ) at different wavelengths will exhibit differing levels of modulation caused by the attenuation of the sample 214.
- the signals 224a and 225a will also exhibit wavelength-dependent modulations caused by the instrumental effects.
- the wavelength-dependent modulations due to the instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 210. System calibration can be performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments,
- the processor 223 can be adapted to correct the measured intensities I c ⁇ ( ⁇ ) and I c2 ( ⁇ ) for modulations caused by the wavelength-dependent instrumental effects.
- the corrected intensities I cl ( ⁇ ) c and I c2 ( ⁇ ) c representing the intensity of the first and second portions 228 and 230 of the return light 220 at different wavelengths can then used to determine the attenuation coefficient ⁇ ( ⁇ ) of the sample 214 as described below.
- the regions ® and ⁇ , of FIG. 2(a) may be at an effective range, symbolized as "R, " from which the collection waveguides 221 and 222 collect the majority of the first and second portions of return light 228 and 230, respectively.
- the effective range "R” will vary with the attenuation of the sample.
- the regions ® and (D, are geometrically symmetric with respect to the aperture 215a of the excitation waveguide 215 and, hence, have identical intensity of the intrinsic fluorescence 229 represented by I ⁇ ( ⁇ ) .
- the wavelength-dependent intensities I cl ( ⁇ ) c and I c2 ( ⁇ ) c can be described by the following equations:
- I cl ( ⁇ ) c I ⁇ ( ⁇ ) e - ⁇ ( ⁇ ) - (R+yl,) (1)
- the attenuation coefficient ⁇ ( ⁇ ) can be calculated independent of the value of "R” from (1) and (2) as follows:
- the attenuation coefficient can be calculated as follows :
- ⁇ ( ⁇ ) ⁇ l/ ⁇ z2'-zl' ⁇ ln ⁇ I cl ( ⁇ ) c /I c2 ( ⁇ ) c ⁇ (4)
- the intrinsic fluorescence, I ⁇ ( ⁇ ) can be restored from either of the signals I cl ( ⁇ ) c or I c2 ( ⁇ ) c (preferably I c2 ( ⁇ ) c where y2 ' « yl ' ) by assuming an average effective range "R" from which most of the intrinsic fluorescence is collected.
- the constant "R” is approximately about 0.2 mm at 308 nm excitation radiation. Therefore, the intrinsic fluorescence I ⁇ ( ⁇ ) can be obtained by substituting the measured I c2 ( ⁇ ) c into equation (2) and solving for I ⁇ ( ⁇ ) using the constant R and the known value y2 ' :
- I ⁇ ( ⁇ ) I c2 ( ⁇ ) c e ⁇ ( ⁇ ) - (R+y2,) (5)
- the absorbance A( ⁇ ) and the percent transmittance %T ( ⁇ ) of the sample can be calculated as follows:
- a ( ⁇ ) log ⁇ l c2 ( ⁇ ) c /I cl ( ⁇ ) c ⁇ ( 6 )
- the source 311 emits laser radiation 312 at a wavelength and intensity capable of inducing fluorescence of the sample 314.
- the laser radiation 312 is reflected by a dichroic mirror 326 into an excitation-collection waveguide 321, which transmits the laser radiation 312 to the sample volume 313 where the laser radiation 312 excites local fluorophores to emit intrinsic fluorescence 329.
- the intensity of the laser 312 should be sufficient to create a sample volume 313 that overlaps with the numerical aperture 319 of the collection-only waveguide 322.
- the dimensions of the sample volume 313 will also depend on the numerical aperture of the excitation-collection waveguide 321, on the wavelength and intensity of the excitation radiation 312 and on the optical properties of the sample 314.
- the intrinsic fluorescence 329 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) of the sample 314.
- the excitation-collection waveguide 321 collects a first portion 328 of the return light 320 directly from the sample volume 313.
- the first portion 328 of the return light 320 is transmitted through the dichroic mirror 326 to the first sensor 316.
- the first sensor 316 generates a first signal 324a representing the intensity I xc ( ⁇ ) of the first portion 328 of the return light 320 at a plurality of wavelengths within a predetermined wavelength band.
- the collection-only waveguide 322 may be positioned such that the aperture 322a is laterally displaced from the excitation-collection waveguide 321 by the distance x3 and axially displaced from the aperture 321a of the excitation- collection waveguide 321 by the range y3.
- the lateral distance x3 is zero while the axial distance y3 is non-zero.
- the apertures 321a and 322a of the waveguides 321 and 322 are preferably positioned in close proximity to or in contact with the sample 314 during use of the LIFAS system 310, as shown in FIG. 3(a).
- the numerical aperture 319 of the collection-only waveguide 322 is selected to include at least a portion of the sample volume 313.
- the collection-only waveguide 322 collects a second portion
- the second sensor 318 generates a second signal 325a representing the intensity I co ( ⁇ ) of the second portion 330 of the return light 320 at a plurality of wavelengths preferably within the same wavelength bands as the signal 324a generated by the first sensor 316.
- a longpass filter is placed in front of the aperture of each of the sensors 316 and 318 to selectively block backscattered excitation radiation. In the embodiment shown in FIG.
- the first and second portions 328 and 330 of the return light 320 experience different attenuation effects due to the unequal path-lengths traversed by the return light 320 from the sample volume 313 to the apertures 321a and 322a of the waveguides 321 and 322, respectively.
- the second portion 330 of the return light 220 collected by the aperture 322a travels an additional path-length through the tissue as compared to the first portion 328 of the return light 320 which is collected by the aperture 321a directly from the sample volume 313.
- the first portion 328 of the return light 320 suffers less path-length-dependent attenuation as compared to the second portion 330 of the return light 320.
- the signals 324a and 325a representing intensity I xc ( ⁇ ) and I co ( ⁇ ) at different wavelengths will exhibit different levels of modulation caused by the sample 314.
- the signals 324a and 325a will also exhibit wavelength- dependent modulations caused by the instrumental effects.
- the wavelength-dependent modulations due to instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 310. System calibration is performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, CT) having a predetermined continuous spectrum to measure the wavelength- dependent instrumental effects of the LIFAS system 310.
- the processor 323 can be adapted to correct the measured intensities I xc ( ⁇ ) and I co ( ⁇ ) for modulations caused by the wavelength-dependent instrumental effects.
- the corrected intensities I xc ( ⁇ ) c and I co ( ⁇ ) c representing the intensity of the first and second portions 328 and 330 of the return light 320 at different wavelengths can then be used by the processor 323 to determine the wavelength-dependent attenuation ⁇ ( ⁇ ) of the sample 314.
- either of the signals 324a or 325a, preferably 324a can be corrected for the effects of attenuation to restore the intrinsic LIF 329 of the fluorophores in the sample volume 313.
- the source 311 is an Xe-Cl excimer laser emitting ultraviolet excitation radiation at a wavelength of 308 nm.
- the waveguides 321 and 322 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability.
- a 1.4 mm diameter optical bundle and a 0. mm optical fiber are used as the excitation-collection and the collection- only waveguides, respectively.
- the collection-only waveguide is a plurality of 0.4 mm optical fibers disposed about the periphery of the excitation-collection waveguide.
- the optical bundle and fibers are made of fused silica which is transparent to the 308 nm ultraviolet radiation.
- the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
- Each of the sensors 316 and 318 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum.
- PDA 1024 element intensified photo diode array
- Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) which measures the intensity of the light spectrum imaged by the PDA and produce the signals 324a and 325a.
- OMA III optical multichannel analyzer
- the processor 323 is a personal computer that is networked to each of the sensors 316 and 318 via the signal paths 324 and 325 to receive the signals 324a and 325a, respectively.
- the method of determining the attenuation coefficient ⁇ ( ⁇ ) and the intrinsic fluorescence I ⁇ ( ⁇ ) of a sample using the embodiment of FIG. 3(a) in accordance with the current invention is as follows.
- "D" represents the effective range, from which the collection waveguide 321 collects a majority of the portion 328 of the return light 320.
- the portion 328 of the return light 320 is collected directly from the sample volume 313 by the excitation-collection waveguide 321. Therefore, the wavelength-dependent intensity I xc ( ⁇ ) c of the portion 328 of the return light 320 collected by the excitation-collection waveguide 321 will be substantially similar to the wavelength-dependent intensity of the return light 320, represented as I 0 ( ⁇ ).
- the return light 320 with the intensity I 0 ( ⁇ ) will suffer additional wavelength-dependent attenuation as it travels the extra path-length to reach the aperture 322a and is collected as the second portion 330 of the return light 320 with the intensity I co ( ⁇ ) c .
- the wavelength-dependent intensity I co ( ⁇ ) c can be approximated by the following equations :
- the attenuation coefficient can be approximated as follows:
- the intrinsic fluorescence, I ⁇ ( ⁇ ) can be restored from either of the signals I xc ( ⁇ ) c or I co ( ⁇ ) c , preferably I xc ( ⁇ ) c , by assuming an average effective range "D" from which most of the intrinsic fluorescence is collected.
- the constant "D” is approximately about 0.2 mm at 308 nm excitation radiation.
- I ⁇ ( ⁇ ) I xc ( ⁇ ) c e ⁇ ( ⁇ ) - D (12)
- the measured attenuation may account for absorption and/or scattering depending on the wavelength band of interest and the nature of the sample. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient ⁇ ( ⁇ ) will represent absorptivity a ( ⁇ ) . Also, the absorbance A( ⁇ ) and the percent transmittance %T ( ⁇ ) of such samples can be calculated as follows:
- a LIFAS system 410 in accordance with the present invention has been adapted for biomedical applications.
- the LIFAS system 410 has been adapted to determine the optical attenuation of biological tissue.
- the laser 411 emits radiation 412 at a wavelength capable of exciting the tissue 414 to emit fluorescence.
- the radiation 412 is directed through an iris 440 at a dichroic mirror 442 which reflects the radiation 412 onto a lens 444 which focuses the radiation 412 onto the proximal tip 445 of an optical fiber 446.
- the adjustable iris 440 is advantageously used to reduce the energy of the radiation 412.
- the adjustable iris 440 can be replaced by any suitable attenuator.
- the probe 448 includes a central optical fiber 446 that is used as the excitation-collection fiber and peripheral optical fibers 450a-h are used as the collection-only fibers.
- the distal end of the optical fibers 446 and 450a-h are incorporated into the optical probe 448.
- the aperture 448a the optical fiber probe 448 is placed in proximity to the tissue 414 so that the aperture 446a of the excitation-collection fiber 446 and apertures 451a-h of the collection-only fibers 450a-h are in contact with the tissue 414. As shown in a partial perspective view in FIG.
- the optical fiber probe 448 includes a central optical fiber 446 and a plurality of optical fibers 450a-h disposed about the periphery of the central optical fiber 446.
- the apertures 451a-h of the distal ends of the collection-only fibers 450a-h are axially displaced by a small distance y3 with respect to the aperture 446a of the excitation-collection fiber 446.
- the return light 420 collected by apertures 451a-h of the collection-only fibers 450a-h pool into the aperture 418a of the sensor 418.
- the optical fibers 446 and 450a-h can advantageously be replaced by optical fiber bundles in order to obtain greater flexibility and durability.
- the central optical fiber 446 can be replaced with an optical fiber bundle 454.
- the excitation radiation 412 is transmitted through the optical fiber 446 to the tissue 414 to induce intrinsic fluorescence of the fluorophores of the tissue 414.
- the intrinsic fluorescence is modulated, for example, by the chromophores and/or scatterers of the tissue 414.
- a first portion 428 of the return light 420 is collected by the optical fiber 446 from the tissue volume that is directly irradiated by the excitation radiation 412 and transmitted through the optical fiber 446 to a first lens 444 where the return light is directed through the dichroic mirror 442 and then focused by a second lens 445 onto the aperture 416a of a first sensor 416.
- the collection-only optical fibers 450a-h collect a second portion 430 of the return light 420 and transmit the second portion 430 of the return light 420 to the second sensor 418.
- longpass filters are placed in front of the apertures 416a and 418a of the sensors 416 and 418 to selectively block backscattered excitation radiation.
- a first signal 424a and a second signal 425a representing the intensity of the first and second portions 428 and 430, respectively, of the return light 420 are generated by the first and second sensors 416 and 418 and transmitted via signal paths 424 and 425 to the processor 423.
- the processor 423 uses the first and second signals 424a and 425a generated by the detectors 416 and 418 to determine the wavelength-dependent attenuation of the sample 414 using equations (8), (9) and (10) as described in the previous embodiment .
- an illumination source 490 emitting visible light 492 is mounted on the probe 448 to act as a spotlight for the operator. Because room illumination can contaminate the spectral measurements of the system 410 by adding background light, use of the illumination source 490 will allow the operator to see and accurately position the probe 448 under low-light conditions.
- the illumination source 490 is configured to illuminate the sample at all times, except when the LIFAS system is monitoring return light from the sample 414.
- the biological electrical signal arising in nerves or contractile tissue, such as muscle, is known as the "action potential" and is caused by sudden changes in the ion conductivity of the cell membrane.
- the occurrence of an action potential in contractile tissue initiates a contraction.
- the action potential propagates and spreads in a wave-like manner to induce a local myocardial contraction wherever it travels.
- An action potential propagating in the tissue local to the aperture 448a of the probe 448 can be detected by the electrode
- the amplified action potential 468 is transmitted to the processor 423 to trigger the acquisition process of the LIFAS system 410 at a pre-selected phase of the tissue contraction or of the cardiac cycle, whichever is applicable .
- a plurality of electrodes or fibers with a conductive coating can be distributed circumferentially about the tip of the optical fiber probe 448.
- the probe 448 can be equipped with three electrodes 470, 472 and 474 arranged in a triangular configuration.
- the action potentials measured by each of the electrodes 470, 472 and 474 are amplified through separate channels of the amplifier 460 and transmitted to the processor 423.
- the processor 423 processes the received signals to determine the direction of propagation of the contraction vector 462.
- the processor detects the phase lead/lag between the action potentials collected by the electrodes 470, 472 and 474 to determine the orientation of the contraction vector 462 with respect to the location of the electrodes 470, 472 and 474.
- the contraction vector 462 shown in FIG. 7(a) is propagating from the tissue site 476a to the site 478a and, hence, as shown in FIG. 7(c), the action potential 474a arrives before the action potential 472a which in turn arrives before the action potential 470a.
- the phase difference or time delay between a pair of action potentials indicates how the contraction vector 462 is centered between the location of the corresponding pair of electrodes.
- the contraction vector 462 propagates from the tissue site 476b to the site 478b.
- the corresponding time of arrival of action potentials 470b, 472b and 474b will vary.
- the processor 423 processes the signals and indicates the direction of the propagation of the contraction to the system operator.
- the direction of propagation can be indicated, for example, by a circular array 496 of light emitting diodes (LED) 498 mounted cirumferentially on the probe 448, as shown in FIG. 8.
- the processor 423 transmits a signal to the LED array 496 so that, for example, only the LED element pointing in the direction of contraction propagation would glow.
- the amplifier 460 can be replaced by any device that can measure the electrical activity of biological tissue such as a differential amplifier, an electrocardiogram (ECG) , an electromyogram (EMG) , an electroencephalogram (EEG) , depending on the LIFAS application.
- ECG electrocardiogram
- EMG electromyogram
- EEG electroencephalogram
- optical fibers with a metallic or electrically conductive coating can be used in place of one or all of the electrodes 464, 470, 472 or 474 to measure the action potential of the tissue.
- conventional ECG is generally not suitable for triggering the acquisition of LIFS or LIFAS systems, since it does not accurately indicate the instantaneous state of myocardial contraction at the sample volume.
- customary ECG using limb or chest leads can be used to trigger data acquisition of the LIFAS system 410 where the sample 414 is non-contractile tissue.
- the light source 411 is preferably a lamp or a laser that emits ultraviolet, visible or infrared radiation.
- the source 411 is an XeCl excimer laser emitting pulses of ultraviolet excitation radiation at 308 nm.
- the optical components used in the acquisition system be made of synthetic quartz (fused silica) to ensures maximal ultraviolet transmission and minimal instrumental fluorescence.
- a nitrogen laser, a helium-cadmium laser, a frequency-multiplied laser, a solid-state laser, an arc lamp or a light-emitting diode can be used as the light source 411.
- the energy of the excitation light 412 is typically between 0.001-lOm Joules. However, it will be appreciated that the selected energy level should be low enough to avoid tissue ablation and/or photobleaching while still being adequate to produce detectable LIF.
- the sensors 416 and 418 are each comprised of a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) detector.
- An optional low fluorescence, long-pass filter (not shown) with a cutoff wavelength above 308 nm, preferably 335 nm (Schott WG335) , is placed before the entrance slit of each spectrograph to selectively block any backscattered excitation radiation from reaching the sensors 416 and 418.
- the entrance slit of the spectrograph preferably has a width of 100 micrometers.
- the spectrograph uses a 150 lines per millimeter diffraction grating to disperse the incoming return light 420 into its spectral components.
- the spectrum formed by the spectrograph is imaged by a detector, preferably an intensified linear photodiode array (Model 1420, EG&G Princeton Applied Research Corporation, Princeton, NJ) facing the output port of the spectrograph.
- the photodiode array generates a plurality of electrical signals representing the intensity of the return light 420 at wavelengths within predetermined wavelength bands.
- the sensors can be constructed of any suitable materials, such as individual light- sensitive diodes with appropriate band-pass filters for the analysis of spectral bands of the return light or an optical spectrum analyzer ("OSA”) for analysis of a broader spectrum. Selection of the return light monitoring device will depend on a variety of factors, including cost, accuracy, resolution, and whether the user is interested in monitoring a single wavelength, a wavelength band or an entire spectrum.
- the optical fiber probe includes a central excitation-collection optical fiber or optical fiber bundle with a plurality of collection-only optical fibers disposed around its periphery
- the probe can take many forms.
- the central optical fiber can be used as the collection-only waveguide while all or some of the peripheral fibers can be used for excitation-collection or collection-only. The latter arrangement is preferred when testing highly-attenuating samples to achieve a better signal-to-noise ratio.
- FIG. 9 shows three alternative geometrical configurations of the collection-only optical fibers 950a-h about the excitation-collection waveguide 946.
- the collection-only waveguides 950a-h are arranged about the excitation-collection waveguide 946 so that their apertures have a helical configuration.
- each successive collection-only waveguide is shifted axially away from the aperture 947 of the excitation-collection waveguide 946, the return light collected by each of the collection-only waveguides 950a-h will be attenuated in varying degrees.
- Use of a probe arrangement having a plurality of collection distances will be useful in measuring the polarization and/or the attenuation of especially, a sample having a higher sensitivity to attenuation due to absorption.
- a probe incorporating a plurality of collection distances have application to a larger variety of samples. For example, where the sample is highly attenuating, the collection- only waveguides having apertures close to the excitation site can be used to collect the return light. Where the sample is lightly attenuating, the return light collected by the waveguides having apertures that are further from the excitation site will be useful in determining the attenuation.
- the collection-only waveguides 950a-c are displaced laterally with respect to the excitation-collection waveguide 946.
- Such a probe configuration will be useful in measuring the polarization and/or the attenuation of the sample where the sample has a higher sensitivity to attenuation due to scattering.
- the return light collected by the waveguide 950c will be useful in measuring attenuation of a lightly attenuating sample.
- the return light measured by the closest waveguide 950a will be useful in measuring the attenuation of a heavily-attenuating sample.
- the collection-only waveguides 950a-c are both axially and laterally displaced with respect to the excitation-collection waveguide 946. This configuration combines the advantages of both of the aforementioned configurations shown in FIGS. 9(a) and 9(b).
- a single sensor 1016 and an associated optical multiplexer 1080 are utilized.
- the multiplexer 1080 is used to switch the input of the sensor 1016 between the excitation- collection optical path (1046, 1044, 1042, 1049, 1046') and the collection-only optical path (1050) such that the return light from each pathway is measured sequentially.
- the processor 1023 sends trigger signals to the source 1011, the sensor 1016 and the optical multiplexer 1080 to synchronize their actions. If the source 1011 is a pulsed laser, two or more radiation pulses are typically required to acquire a single attenuation measurement using the multiplexed system 1010.
- a single laser pulse can be used if the laser pulse lasts long enough to sustain the emission of return light 1020 during the minimum period of time required by the optical multiplexer 1080 and associated sensor 1016 to acquire the spectral measurements from both the excitation-collection and the collection only optical paths.
- the preferred embodiment of the LIFAS system 1010 is similar to that of 410, except that the system 1010 utilizes an electromagnetic dual port shutter as the optical multiplexer 1080 associated with a single sensor 1016 in a configuration where the portion 1028 and the portion 1030 of the return light 1020 are measured sequentially.
- the LIFAS methods and devices of the present invention can be used advantageously for the in-vivo diagnosis of hypoxia and ischemia of biological tissue.
- Hypoxia is a deficiency in the amount of oxygen reaching the tissue, e.g., due to pneumonia
- ischemia is a localized reduction in arterial blood perfusion, e . g. , due to a narrowing of arteries by spasm or disease.
- Ischemia can also result from hemorrhage of an arterial wound or during surgical procedure that temporarily interrupts the blood flow to a body region.
- the present invention describes new criteria and methods for the discrimination between normal, ischemic and hypoxic biological tissue, including, in particular renal and myocardial tissue, as follows.
- LIFAS laser induced fluorescence attenuation
- the LIFAS-derived LIFA spectra of normal and ischemic rabbit kidney are shown in FIG. 12.
- the LIFA spectra shown in FIG. 12 are acquired using a LIFAS system employing 308 nm excitation radiation produced by an XeCl excimer laser.
- This LIFAS system uses a 335 nm longpass filter (Schott WG335) to cutoff backscattered excitation radiation form the collected return light.
- the LIFA values below 350 nm are not reliable.
- the LIFA values in the wavelength band about 480 nm have the highest signal-to-noise ratio and hence measurement accuracy.
- the LIFA of ischemic tissue is lower than the LIFA of normal tissue over the entire spectrum and is particularly low in the region from 350 to 450 nm.
- the LIFA, absorbance or percent transmittance at a predetermined wavelength or wavelength bands can be used for the detection of ischemia or hypoxia.
- predictive models, spectral recognition techniques and associated classifiers can be applied to identify whether a given LIFA, absorbance or percent transmittance spectrum has been acquired from normal, ischemic or hypoxic tissue.
- the classifiers can be initially trained with LIFA, at a predetermined wavelength or wavelength bands acquired from tissue with a known state of perfusion or oxygenation.
- the [I xc (480) c , I co (480) c ] from normal and oxygen deficient tissue tend to cluster in two linearly separable regions of the two dimensional I xc ( ⁇ ) c -I co ( ⁇ ) c space.
- a simple linear or nonlinear classifier function can be trained on a set of [I xc ( ⁇ ) c, I co ( ⁇ ) c ] pairs measured using a LIFAS system from normal, ischemic and hypoxic tissue.
- Other classifiers such as artificial neural networks (ANN) are also being used.
- the trained classifier function can then be used to classify an unknown [I xc ( ⁇ ) c , I co ( ⁇ ) c ] pair as normal, ischemic or hypoxic.
- a "nearest neighbor” (NN) classifier has been found to perform satisfactorily.
- the NN classifier checks the proximity of an unknown [I xc (480) c , I co (480) c ] pair to clusters of predetermined [I xc (480) c , I co (480) c ] pairs measured from known normal, ischemic and hypoxic tissue.
- Other classifiers such as artificial neural networks (ANN) can also be utilized.
- ANN artificial neural networks
- [I xc ( ⁇ ) c , I co ( ⁇ ) c ] at other single or multiple pre-selected wavelengths can also be used.
- ⁇ max _ ⁇ An additional parameter for the classification of normal, ischemic and hypoxic tissue, is the wavelength of the peak transmittance of the tissue, symbolized hereafter as ⁇ max _ ⁇ , especially in the 450-500 nm band.
- ⁇ max _ ⁇ is the wavelength of the peak I co ( ⁇ ) c in the 450-500 nm band, symbolized hereafter as ⁇ , instruct ax _ co .
- Both ⁇ max _ ⁇ and meticulous ax _ co shift towards shorter wavelengths as the hemoglobin in the tissue becomes deoxygenated .
- FIG. 14 shows I co ( ⁇ ) c spectra that are acquired using the LIFAS system shown in FIG.
- ⁇ max _ co shifts to a shorter wavelength as the tissue becomes hypoxic; whereas the ⁇ ma ⁇ - co °f normal tissue shifts to a longer wavelength as the tissue becomes hyperoxic.
- ⁇ max _ co varies between about 480 and 500 nm as blood or hemoglobin oxygenation varies between deoxygenated to oxygenated, respectively.
- a separation border can be identified at about 489.5 nm to separate ⁇ max _ co of normal tissue (peaks above 489.5 nm) from hypoxic/ischemic tissue (peaks below 489.5 nm) .
- a simple classifier can be trained to identify tissue as hypoxic if its ⁇ raax _ co is below 489.5, and vice versa.
- the degree of hypoxia is determined from the magnitude of the shift in ⁇ max . c0 from the normal value, the smaller the shift the subtle the hypoxia.
- the presence of renal or myocardial ischemia can be detected from the shape of the main lobe of the common LIF (e.g. I xc ( ⁇ ) c ) spectrum in the wavelength band 350-450 nm.
- the common LIF can be acquired via an excitation-collection waveguide of a LIFAS or a conventional LIFS system.
- FIGS. 16(a) and (b) show typical LIF spectra acquired from normal and ischemic rabbit kidneys at an excitation wavelength of 308 nm.
- the shape of the main lobe of the LIF acquired from normal tissue is skewed to the right (a positive skewness value) .
- Skewness can be measured by a single parameter which indicates the degree of asymmetry of a lobe or curve around its mean value. For a symmetrical lobe the skewness is zero, however for an asymmetrical lobe the skewness can be either positive or negative depending on the shape.
- the skewness "S" is given by:
- X is the mean intensity of the lobe
- ⁇ is the wavelength
- ⁇ is the number of wavelength measurements in the lobe.
- tissue ischemia can be detected by monitoring the skewness of the main lobe of a common (i.e. modulated) LIF acquired using an excitation-collection fiber from the tissue.
- a zero or negative skewness value indicates that the LIF spectra is acquired from ischemic tissue, while a positive skewness will indicate normally perfused tissue.
- the bottom of the central spectral valley is considered as the baseline for the definition of the main lobe as indicated in FIG. 16.
- the intrinsic LIF of normal biological tissue will have a spectrum with a single peak resembling that of the main tissue fluorophores, collagen and elastin.
- the intrinsic LIF develops a secondary peak or a hump at about 470-490 nm which is associated with the peak fluorescence emission of ⁇ ADH .
- the appearance of this hump in an intrinsic LIF spectrum is a direct indication of oxygen deficiency resulting from hypoxia or ischemia.
- this ⁇ ADH-related hump is not readily detectable in common LIF spectra because of an overlapping spurious hump created by an intensity dip associated with peak hemoglobin absorption at about 410 nm.
- the intrinsic LIF spectrum of normal kidney does not exhibit the second hump created by the spectral valley associated with hemoglobin absorption.
- the intrinsic fluorescence of hypoxic myocardium exhibits a secondary hump indicating high NADH concentration.
- ischemia or hypoxia can be detected from a LIFAS-derived intrinsic LIF spectrum by assessing its NADH-related secondary hump either visually or through simple qualitative analysis.
- the magnitude of the NADH hump will indicate the level of oxygen deficiency caused by hypoxia or ischemia while its absence indicate normal oxygenation.
- ischemia or hypoxia detection techniques use predetermined ratios of spectral intensities at wavelengths associated with NADH, elastin and collagen to discriminate normal from abnormal tissue.
- the magnitude of the intensity does not fully characterize spectral changes associated with ischemia or hypoxia. Instead, it is desirable to undertake spectral classification based on the shape of wavelength bands or the whole spectrum.
- the introduction of the LIFAS methods and devices of the present invention enables the application of a new modeling approach for the measurement of ischemia and hypoxia.
- the approach relies on methods of multivariate linear regression (MLR) , principle component regression (PCR) and the method of partial least squares (PLS) .
- MLR multivariate linear regression
- PCR principle component regression
- PLS partial least squares
- the MLR, PCR and the PLS models are trained with LIFA or absorbance spectra as their input and the concentration of both oxygenated and deoxygenated hemoglobin as their outputs.
- the blood content (i.e. quantity of blood) in the tissue is determined by combining the concentrations of both oxygenated and deoxygenated hemoglobin.
- the MLR, PCR and the PLS models are trained with LIFA spectra from normal, hypoxic or ischemic rabbit heart and kidney.
- a model can be used to predict the concentrations of oxygenated and deoxygenated hemoglobin if given a LIFA spectrum measured from tissue with unknown oxygenation.
- the presence and level of hypoxia can be determined by comparing the latter-predicted concentrations values to those known values previously measured from normal tissue. Hypoxic tissue have less oxygenated and more deoxygenated hemoglobin concentrations than normal tissue.
- the presence and level of ischemia can be determined by combining the predicted concentrations to determine the total blood content and then comparing the total blood content to known values of blood content measured in normal tissue. Ischemic tissue will have a lower blood content than normally perfused tissue.
- the PLS model was found to have the optimal accuracy in detecting the presence and level of ischemia and hypoxia .
- a new mathematical classifier has been developed and applied to categorize spectral data for ischemia or hypoxia detection.
- the recent multicriteria associative memories (MAM) technique is modified to perform as a data classifier. Similar to existing classifiers, the MAM requires initial training on a set of input-output data pairs. The training process of the MAM classifier involves the calculation of the weights matrix M( ⁇ ) from the input-output data set using the following learning rule :
- the matrices "S” and “R” holds the input and output training vectors as their columns, respectively.
- the superscripts ⁇ and “1 indicate matrix transpose and inversion, respectively, and "I” is the identity matrix.
- the parameter ⁇ is initially set to 0.98; however, it can assume any value between 0 and 1 depending on the noise of the system.
- the output "r" for an unknown input “s” can be readily calculated from the dot product:
- the MAM classifier is initially trained with LIFA (or absorbance) spectra acquired from normal or ischemic tissue as the training inputs.
- the corresponding normal or ischemic state can be encoded as, for example, "-1" or "1,” respectively and used as the training outputs. Therefore, the training LIFA spectra are placed as columns of the input matrix "S” while their corresponding state-coded values are arranged in the same order as elements of the output row vector "R.” The number of columns in "S” and elements in “R” are equal to the number of available training sets.
- a trained MAM matrix can determine whether an unknown LIFA spectrum "s ?
- the MAM classifier can be applied for the detection of hypoxia and the discrimination between normal, ischemic and hypoxic tissue. It should be apparent that common or intrinsic LIF spectra can replace LIFA spectra as the classifier input. In addition, this input can be an entire spectrum, a re-sampled version of a spectrum or a set of statistical parameters or features characterizing a spectrum. Similarly, actual ischemia or hypoxia levels can be used as the classifier outputs instead of the binary coded output values employed in the above demonstration. In this case a linear transfer function may be used to categorize the output "r" of the MAM classifier.
- the MAM technique outperformed the commonly-used artificial neural network (ANN) classifier in accurately classifying LIF/LIFA spectra resulting from normal and ischemic tissue.
- ANN artificial neural network
- the superiority of the MAM classifier is most probably due to its insensitivity to spectral noise that might be present in LIF/LIFA spectra measured from biological systems.
- the foregoing MAM classifier is currently applied to discriminate spectral data for the purpose of ischemia or hypoxia detection, it is understood that those skilled in the art may apply it in various ways for different classification purposes .
- LIFAS devices and methods can be applied to tissue characterization, i.e., to differentiate between normal and diseased tissue, for tissue diagnostics and malignancy detection.
- Current LIFS techniques use the intensity spectrum of modulated LIF to identify malignant (cancerous and pre-cancerous ) tissue and classify its type.
- LIFAS techniques offer a unique tissue characterizing capability not offered by conventional LIFS, based upon measurement of the attenuation spectrum.
- FIGS. 17(a)-(d) A simple demonstration of LIFAS diagnostic capability is shown in FIGS. 17(a)-(d). Although normal kidney and heart tissue are different in nature, their common LIF spectra, shown in FIGS. 17(a) and (b) are almost identical and, hence, are not so usefl for classifiation purposes. However, heart and kidney LIFA spectra, shown in FIG. 17(c) and d are different in terms of both shape and peak attenuation values. Thus, LIFAS techniques offer better tissue identification power than conventional LIFS techniques.
- LIFAS methods and devices will include laser removal of decorative tattoos, detection of the in-vivo glucose level, assessment of the degree of burn trauma, detection of atherosclerotic plaque, angioplasty, measurement of acidity or alkalinity, pH measurement, the analysis of biochemical fluids, and the like.
- measurement of the in vivo skin absorption using LIFAS methods and devices in accordance with the present invention can said in the selection of optimal laser wavelengths for removing tattoos of different colors.
- LIFAS techniques can be used to determine absorbance from a hypodermic sample volume, the skin color and the depth of the tattoo dye can be more accurately characterized than in surface reflectance techniques.
- burn injury assessment can be accomplished by using LIFAS techniques to measure the depth of burn by probing for the presence of blood perfusion at varying locations within the tissue.
- LIFAS techniques can also be used to determine the absorbance or turbidity of a liquid in-situ without the necessity of extracting a sample for use in a spectrometer.
- LIFAS devices and methods can be used to measure the absorbance and/or turbidity of materials and mixtures in medical, food, beverage, detergent, plastic, glass, oil, paint, textile, and semiconductor applications.
- concentration of the pure components of the mixture can be determined from the absorbance spectrum using chemometric techniques such as multivariate regression (MLR) , partial least squares (PLS) or artificial neural networks described above.
- MLR multivariate regression
- PLS partial least squares
- artificial neural networks described above.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98926475A EP0995095B1 (en) | 1997-07-07 | 1998-06-09 | Method for laser induced fluorescence attenuation spectroscopy (lifas) |
AU78306/98A AU752061B2 (en) | 1997-07-07 | 1998-06-09 | Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) |
JP2000502389A JP2001509589A (en) | 1997-07-07 | 1998-06-09 | Method and apparatus for laser-induced fluorescence decay spectroscopy |
DE69829664T DE69829664D1 (en) | 1997-07-07 | 1998-06-09 | METHOD FOR LASER-INDUCED FLUORESCENT DAMPING SPECTROSCOPY |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/889,017 | 1997-07-07 | ||
US08/889,017 US6124597A (en) | 1997-07-07 | 1997-07-07 | Method and devices for laser induced fluorescence attenuation spectroscopy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999002956A2 true WO1999002956A2 (en) | 1999-01-21 |
WO1999002956A3 WO1999002956A3 (en) | 1999-04-29 |
Family
ID=25394356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011937 WO1999002956A2 (en) | 1997-07-07 | 1998-06-09 | Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) |
Country Status (6)
Country | Link |
---|---|
US (3) | US6124597A (en) |
EP (2) | EP1562038A3 (en) |
JP (1) | JP2001509589A (en) |
AU (1) | AU752061B2 (en) |
DE (1) | DE69829664D1 (en) |
WO (1) | WO1999002956A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001052725A1 (en) * | 2000-01-21 | 2001-07-26 | Instrumentation Metrics, Inc. | Classification and characterization of tissue through features related to adipose tissue |
WO2001060246A2 (en) * | 2000-02-18 | 2001-08-23 | Argose, Inc. | Multivariate analysis of green to ultraviolet spectra of cell and tissue samples |
WO2002024048A2 (en) | 2000-09-25 | 2002-03-28 | Vital Medical Ltd. | Apparatus and method for monitoring tissue vitality parameters |
US6377841B1 (en) | 2000-03-31 | 2002-04-23 | Vanderbilt University | Tumor demarcation using optical spectroscopy |
JP2003528678A (en) * | 2000-03-31 | 2003-09-30 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus for localizing anomalous regions in a turbid medium |
WO2004039254A1 (en) * | 2002-10-31 | 2004-05-13 | Shanghai Shengbiao Science And Technology Co., Ltd. | A laser-induced fluorescence method for precancerous lesion diagnosis and an endoscope precancerous lesion diagnosis apparatus thereof |
USRE39672E1 (en) | 1997-07-07 | 2007-06-05 | Cedars-Sinai Medical Center | Method and devices for laser induced fluorescence attenuation spectroscopy |
US7313424B2 (en) | 2002-03-20 | 2007-12-25 | Critisense Ltd. | Diagnosis of body metabolic emergency state |
US7558609B2 (en) | 2004-04-06 | 2009-07-07 | National University Corporation Okayama University | Cerebral-ischemia supervisory monitor |
WO2016166067A1 (en) * | 2015-04-17 | 2016-10-20 | Koninklijke Philips N.V. | Detection of anisotropic biological tissue |
JP2016540558A (en) * | 2013-11-14 | 2016-12-28 | ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity | System and method for determining the depth of damage using fluorescence imaging |
CN109270044A (en) * | 2018-11-28 | 2019-01-25 | 安徽理工大学 | A kind of laser induced fluorescence vegetable oil doping strong tea water identification method |
Families Citing this family (404)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9702434A (en) | 1991-03-07 | 1998-05-31 | Masimo Corp | Signal processing apparatus. |
US5490505A (en) | 1991-03-07 | 1996-02-13 | Masimo Corporation | Signal processing apparatus |
US5638818A (en) | 1991-03-21 | 1997-06-17 | Masimo Corporation | Low noise optical probe |
EP1905352B1 (en) | 1994-10-07 | 2014-07-16 | Masimo Corporation | Signal processing method |
US8019400B2 (en) | 1994-10-07 | 2011-09-13 | Masimo Corporation | Signal processing apparatus |
US5758644A (en) | 1995-06-07 | 1998-06-02 | Masimo Corporation | Manual and automatic probe calibration |
US6826422B1 (en) | 1997-01-13 | 2004-11-30 | Medispectra, Inc. | Spectral volume microprobe arrays |
US6229856B1 (en) | 1997-04-14 | 2001-05-08 | Masimo Corporation | Method and apparatus for demodulating signals in a pulse oximetry system |
US6002952A (en) | 1997-04-14 | 1999-12-14 | Masimo Corporation | Signal processing apparatus and method |
JP3667947B2 (en) * | 1997-08-29 | 2005-07-06 | 富士写真フイルム株式会社 | Fluorescence image reader |
KR20010040418A (en) * | 1998-01-26 | 2001-05-15 | 자밀라 제트. 허벡 | Fluorescence imaging endoscope |
US7899518B2 (en) | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
US20020091324A1 (en) * | 1998-04-06 | 2002-07-11 | Nikiforos Kollias | Non-invasive tissue glucose level monitoring |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
ATE521277T1 (en) | 1998-06-03 | 2011-09-15 | Masimo Corp | STEREO PULSE OXIMETER |
USRE41912E1 (en) | 1998-10-15 | 2010-11-02 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatus |
US7245953B1 (en) | 1999-04-12 | 2007-07-17 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatii |
US6721585B1 (en) | 1998-10-15 | 2004-04-13 | Sensidyne, Inc. | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
US6678541B1 (en) * | 1998-10-28 | 2004-01-13 | The Governmemt Of The United States Of America | Optical fiber probe and methods for measuring optical properties |
AU759282B2 (en) | 1998-12-23 | 2003-04-10 | Medispectra, Inc. | Systems and methods for optical examination of samples |
US6463311B1 (en) | 1998-12-30 | 2002-10-08 | Masimo Corporation | Plethysmograph pulse recognition processor |
US6684090B2 (en) | 1999-01-07 | 2004-01-27 | Masimo Corporation | Pulse oximetry data confidence indicator |
US6770028B1 (en) * | 1999-01-25 | 2004-08-03 | Masimo Corporation | Dual-mode pulse oximeter |
US20020140675A1 (en) * | 1999-01-25 | 2002-10-03 | Ali Ammar Al | System and method for altering a display mode based on a gravity-responsive sensor |
DE60024059T2 (en) * | 1999-01-26 | 2006-07-20 | Newton Laboratories, Inc., Woburn | DEVICE FOR AUTOFLUORESCENT IMAGING FOR AN ENDOSCOPE |
US6360114B1 (en) | 1999-03-25 | 2002-03-19 | Masimo Corporation | Pulse oximeter probe-off detector |
DE19922812C2 (en) * | 1999-05-19 | 2001-10-25 | Merck Patent Gmbh | Measurement of turbidity using reflectometry |
US8229549B2 (en) | 2004-07-09 | 2012-07-24 | Tyco Healthcare Group Lp | Surgical imaging device |
US6515273B2 (en) | 1999-08-26 | 2003-02-04 | Masimo Corporation | System for indicating the expiration of the useful operating life of a pulse oximetry sensor |
US6377829B1 (en) | 1999-12-09 | 2002-04-23 | Masimo Corporation | Resposable pulse oximetry sensor |
US6950687B2 (en) | 1999-12-09 | 2005-09-27 | Masimo Corporation | Isolation and communication element for a resposable pulse oximetry sensor |
US6902935B2 (en) * | 1999-12-15 | 2005-06-07 | Medispectra, Inc. | Methods of monitoring effects of chemical agents on a sample |
AU2001237066A1 (en) | 2000-02-18 | 2001-08-27 | Argose, Inc. | Generation of spatially-averaged excitation-emission map in heterogeneous tissue |
AU6501201A (en) * | 2000-06-01 | 2001-12-11 | Science Applic Int Corp | Systems and methods for monitoring health and delivering drugs transdermally |
US6430525B1 (en) | 2000-06-05 | 2002-08-06 | Masimo Corporation | Variable mode averager |
EP2064989B1 (en) | 2000-08-18 | 2012-03-21 | Masimo Corporation | Dual-mode pulse oximeter |
EP1319939A4 (en) * | 2000-09-22 | 2005-11-23 | Organo Corp | Concentration measurer |
US6839661B2 (en) * | 2000-12-15 | 2005-01-04 | Medispectra, Inc. | System for normalizing spectra |
US6704109B2 (en) * | 2001-01-23 | 2004-03-09 | Schlumberger Technology Corporation | Downhole fluorescence detection apparatus |
US7142306B2 (en) * | 2001-01-23 | 2006-11-28 | Schlumberger Technology Corporation | Optical probes and probe systems for monitoring fluid flow in a well |
US7139598B2 (en) * | 2002-04-04 | 2006-11-21 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence |
US20070276199A1 (en) * | 2002-04-04 | 2007-11-29 | Ediger Marwood N | Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence |
WO2002085218A2 (en) | 2001-04-20 | 2002-10-31 | Power Medical Interventions, Inc. | Bipolar or ultrasonic surgical device |
DE60227162D1 (en) * | 2001-04-20 | 2008-07-31 | Power Med Interventions Inc | ILLUSTRATION DEVICE |
US6796710B2 (en) * | 2001-06-08 | 2004-09-28 | Ethicon Endo-Surgery, Inc. | System and method of measuring and controlling temperature of optical fiber tip in a laser system |
US6850787B2 (en) | 2001-06-29 | 2005-02-01 | Masimo Laboratories, Inc. | Signal component processor |
US6697658B2 (en) | 2001-07-02 | 2004-02-24 | Masimo Corporation | Low power pulse oximeter |
WO2003032808A2 (en) | 2001-10-15 | 2003-04-24 | University Of Massachusetts | Tissue oxygen measurement system |
US6750006B2 (en) | 2002-01-22 | 2004-06-15 | Microbiosystems, Limited Partnership | Method for detecting the presence of microbes and determining their physiological status |
US7186990B2 (en) * | 2002-01-22 | 2007-03-06 | Microbiosystems, Limited Partnership | Method and apparatus for detecting and imaging the presence of biological materials |
US7211377B1 (en) | 2002-01-22 | 2007-05-01 | Microbiosystems, Limited Partnership | Method for detecting the presence of dormant cryptobiotic microorganisms |
US7355512B1 (en) | 2002-01-24 | 2008-04-08 | Masimo Corporation | Parallel alarm processor |
CN100443061C (en) | 2002-01-30 | 2008-12-17 | 能量医学介入公司 | Surgical imaging device |
US6850788B2 (en) | 2002-03-25 | 2005-02-01 | Masimo Corporation | Physiological measurement communications adapter |
US8131332B2 (en) * | 2002-04-04 | 2012-03-06 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence of various sites |
US8140147B2 (en) * | 2002-04-04 | 2012-03-20 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using a flexible probe to determine tissue fluorescence of various sites |
US20080009689A1 (en) * | 2002-04-09 | 2008-01-10 | Benaron David A | Difference-weighted somatic spectroscopy |
US20070096039A1 (en) * | 2002-05-03 | 2007-05-03 | Rakesh Kapoor | Evaluation Of Multicomponent Mixtures Using Modulated Light Beams |
WO2005075963A1 (en) * | 2002-05-03 | 2005-08-18 | Rakesh Kapoor | Evaluation of multicomponent mixtures using modulated light beams |
US6818903B2 (en) * | 2002-07-09 | 2004-11-16 | Medispectra, Inc. | Method and apparatus for identifying spectral artifacts |
WO2004005895A1 (en) * | 2002-07-09 | 2004-01-15 | Medispectra, Inc. | Methods and apparatus for characterization of tissue samples |
US7103401B2 (en) * | 2002-07-10 | 2006-09-05 | Medispectra, Inc. | Colonic polyp discrimination by tissue fluorescence and fiberoptic probe |
US6768918B2 (en) | 2002-07-10 | 2004-07-27 | Medispectra, Inc. | Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof |
EP1545289B1 (en) | 2002-09-30 | 2010-04-28 | Power Medical Interventions, LLC | Self-contained sterilizable surgical system |
US6970792B1 (en) | 2002-12-04 | 2005-11-29 | Masimo Laboratories, Inc. | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US7919713B2 (en) | 2007-04-16 | 2011-04-05 | Masimo Corporation | Low noise oximetry cable including conductive cords |
US6920345B2 (en) | 2003-01-24 | 2005-07-19 | Masimo Corporation | Optical sensor including disposable and reusable elements |
JP2006522938A (en) * | 2003-03-31 | 2006-10-05 | ゾロ テクノロジーズ,インコーポレイティド | Method and apparatus for combustion monitoring and control |
DE10315541A1 (en) * | 2003-04-04 | 2004-10-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method of determining the degree of freshness of food products is based on the wavelength and radiation intensity of emitted florescent radiation |
US7181219B2 (en) * | 2003-05-22 | 2007-02-20 | Lucent Technologies Inc. | Wireless handover using anchor termination |
US7003338B2 (en) | 2003-07-08 | 2006-02-21 | Masimo Corporation | Method and apparatus for reducing coupling between signals |
US7500950B2 (en) | 2003-07-25 | 2009-03-10 | Masimo Corporation | Multipurpose sensor port |
JP2007500529A (en) * | 2003-07-31 | 2007-01-18 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus with variable numerical aperture for determining the properties of fluid flowing through a biological tube structure |
US7254431B2 (en) | 2003-08-28 | 2007-08-07 | Masimo Corporation | Physiological parameter tracking system |
CN100998499B (en) * | 2003-10-28 | 2013-07-24 | 薇拉莱特公司 | Determination of a measure of a glycation end-product or disease state using tissue fluorescence |
US7483729B2 (en) | 2003-11-05 | 2009-01-27 | Masimo Corporation | Pulse oximeter access apparatus and method |
US7587236B2 (en) * | 2004-01-08 | 2009-09-08 | Lawrence Livermore National Security, Llc | Optical spectroscopy for the detection of ischemic tissue injury |
US7438683B2 (en) | 2004-03-04 | 2008-10-21 | Masimo Corporation | Application identification sensor |
US7415297B2 (en) | 2004-03-08 | 2008-08-19 | Masimo Corporation | Physiological parameter system |
CA2464029A1 (en) | 2004-04-08 | 2005-10-08 | Valery Telfort | Non-invasive ventilation monitor |
DE102004024494B4 (en) * | 2004-05-16 | 2019-10-17 | Dürr Dental SE | Medical camera |
US7640046B2 (en) * | 2004-06-18 | 2009-12-29 | Cardiac Pacemakers, Inc. | Methods and apparatuses for localizing myocardial infarction during catheterization |
US7343186B2 (en) | 2004-07-07 | 2008-03-11 | Masimo Laboratories, Inc. | Multi-wavelength physiological monitor |
US9341565B2 (en) | 2004-07-07 | 2016-05-17 | Masimo Corporation | Multiple-wavelength physiological monitor |
US7937128B2 (en) | 2004-07-09 | 2011-05-03 | Masimo Corporation | Cyanotic infant sensor |
US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
CN101137323A (en) * | 2004-12-09 | 2008-03-05 | 弹性医疗系统有限责任公司 | Apparatus and method for continuous real-time trace biomolecular sampling, analysis and delivery |
US7491943B2 (en) * | 2005-01-13 | 2009-02-17 | Whitehead Institute For Biomedical Research | Method and apparatus for UV imaging |
US20060189871A1 (en) | 2005-02-18 | 2006-08-24 | Ammar Al-Ali | Portable patient monitor |
US7596398B2 (en) | 2005-03-01 | 2009-09-29 | Masimo Laboratories, Inc. | Multiple wavelength sensor attachment |
EP1874178A4 (en) | 2005-04-13 | 2009-12-09 | Glucolight Corp | Method for data reduction and calibration of an oct-based blood glucose monitor |
CA2610856A1 (en) * | 2005-06-13 | 2006-12-28 | Stratagene California | System and method for fluorescence excitation and detection having distinct optical paths |
DE102005045906B4 (en) * | 2005-09-26 | 2007-11-29 | Siemens Ag | Device for receiving a tissue containing a fluorescent dye |
US7962188B2 (en) | 2005-10-14 | 2011-06-14 | Masimo Corporation | Robust alarm system |
US7530942B1 (en) | 2005-10-18 | 2009-05-12 | Masimo Corporation | Remote sensing infant warmer |
US8233955B2 (en) | 2005-11-29 | 2012-07-31 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
EP1962671A2 (en) * | 2005-12-03 | 2008-09-03 | Masimo Corporation | Physiological alarm notification system |
US7847941B2 (en) * | 2005-12-07 | 2010-12-07 | Los Alamos National Security, Llc | Fiber optical assembly for fluorescence spectrometry |
US8333874B2 (en) * | 2005-12-09 | 2012-12-18 | Flexible Medical Systems, Llc | Flexible apparatus and method for monitoring and delivery |
US7990382B2 (en) | 2006-01-03 | 2011-08-02 | Masimo Corporation | Virtual display |
US8182443B1 (en) | 2006-01-17 | 2012-05-22 | Masimo Corporation | Drug administration controller |
US20090306533A1 (en) * | 2006-01-26 | 2009-12-10 | Rousche Patrick J | Stroke Inducing and Monitoring System and Method for Using the Same |
GB0604231D0 (en) * | 2006-03-02 | 2006-04-12 | Ucl Biomedica Plc | Cancer detection system |
US20070244377A1 (en) * | 2006-03-14 | 2007-10-18 | Cozad Jenny L | Pulse oximeter sleeve |
US8219172B2 (en) | 2006-03-17 | 2012-07-10 | Glt Acquisition Corp. | System and method for creating a stable optical interface |
US7846390B2 (en) * | 2006-03-30 | 2010-12-07 | King Fahd University Of Petroleum And Minerals | Apparatus and method for measuring concentrations of fuel mixtures using depth-resolved laser-induced fluorescence |
US9176141B2 (en) | 2006-05-15 | 2015-11-03 | Cercacor Laboratories, Inc. | Physiological monitor calibration system |
US7941199B2 (en) | 2006-05-15 | 2011-05-10 | Masimo Laboratories, Inc. | Sepsis monitor |
US8998809B2 (en) | 2006-05-15 | 2015-04-07 | Cercacor Laboratories, Inc. | Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices |
US8028701B2 (en) | 2006-05-31 | 2011-10-04 | Masimo Corporation | Respiratory monitoring |
US10188348B2 (en) | 2006-06-05 | 2019-01-29 | Masimo Corporation | Parameter upgrade system |
US20080039735A1 (en) * | 2006-06-06 | 2008-02-14 | Hickerson Barry L | Respiratory monitor display |
US20080064965A1 (en) * | 2006-09-08 | 2008-03-13 | Jay Gregory D | Devices and methods for measuring pulsus paradoxus |
USD614305S1 (en) | 2008-02-29 | 2010-04-20 | Masimo Corporation | Connector assembly |
US8315683B2 (en) | 2006-09-20 | 2012-11-20 | Masimo Corporation | Duo connector patient cable |
US8457707B2 (en) | 2006-09-20 | 2013-06-04 | Masimo Corporation | Congenital heart disease monitor |
USD609193S1 (en) | 2007-10-12 | 2010-02-02 | Masimo Corporation | Connector assembly |
US20080103375A1 (en) * | 2006-09-22 | 2008-05-01 | Kiani Massi E | Patient monitor user interface |
US9161696B2 (en) | 2006-09-22 | 2015-10-20 | Masimo Corporation | Modular patient monitor |
US8840549B2 (en) | 2006-09-22 | 2014-09-23 | Masimo Corporation | Modular patient monitor |
US9192329B2 (en) | 2006-10-12 | 2015-11-24 | Masimo Corporation | Variable mode pulse indicator |
US20080094228A1 (en) * | 2006-10-12 | 2008-04-24 | Welch James P | Patient monitor using radio frequency identification tags |
US8265723B1 (en) | 2006-10-12 | 2012-09-11 | Cercacor Laboratories, Inc. | Oximeter probe off indicator defining probe off space |
US9861305B1 (en) | 2006-10-12 | 2018-01-09 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US7880626B2 (en) | 2006-10-12 | 2011-02-01 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
WO2008045538A2 (en) | 2006-10-12 | 2008-04-17 | Masimo Corporation | Perfusion index smoother |
US8255026B1 (en) | 2006-10-12 | 2012-08-28 | Masimo Corporation, Inc. | Patient monitor capable of monitoring the quality of attached probes and accessories |
DE102006048317A1 (en) * | 2006-10-12 | 2008-04-17 | Robert Bosch Gmbh | Optical fiber sensor for optical measuring device i.e. interferometric measuring device, has optical fiber modularly provided with mechanically stabilizing coating in area of fiber end piece and/or in area of mechanical receiver |
US8600467B2 (en) | 2006-11-29 | 2013-12-03 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US8414499B2 (en) | 2006-12-09 | 2013-04-09 | Masimo Corporation | Plethysmograph variability processor |
US8852094B2 (en) | 2006-12-22 | 2014-10-07 | Masimo Corporation | Physiological parameter system |
US7791155B2 (en) | 2006-12-22 | 2010-09-07 | Masimo Laboratories, Inc. | Detector shield |
US8652060B2 (en) | 2007-01-20 | 2014-02-18 | Masimo Corporation | Perfusion trend indicator |
EP2118642B1 (en) * | 2007-02-12 | 2015-09-02 | Koninklijke Philips N.V. | Wiregrid monitor device |
US8101426B2 (en) * | 2007-03-02 | 2012-01-24 | Icyt Mission Technology, Inc. | System and method for the measurement of multiple fluorescence emissions in a flow cytometry system |
EP2476369B1 (en) | 2007-03-27 | 2014-10-01 | Masimo Laboratories, Inc. | Multiple wavelength optical sensor |
US8374665B2 (en) | 2007-04-21 | 2013-02-12 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US8764671B2 (en) | 2007-06-28 | 2014-07-01 | Masimo Corporation | Disposable active pulse sensor |
AU2008311221B2 (en) | 2007-07-13 | 2014-08-21 | University Of Massachusetts | Physical performance monitoring and monitors |
US8048040B2 (en) | 2007-09-13 | 2011-11-01 | Masimo Corporation | Fluid titration system |
EP2227843B1 (en) | 2007-10-12 | 2019-03-06 | Masimo Corporation | Connector assembly |
US8310336B2 (en) | 2008-10-10 | 2012-11-13 | Masimo Corporation | Systems and methods for storing, analyzing, retrieving and displaying streaming medical data |
US8274360B2 (en) | 2007-10-12 | 2012-09-25 | Masimo Corporation | Systems and methods for storing, analyzing, and retrieving medical data |
US8355766B2 (en) | 2007-10-12 | 2013-01-15 | Masimo Corporation | Ceramic emitter substrate |
US8553337B2 (en) * | 2007-11-12 | 2013-10-08 | Cornell University | Multi-path, multi-magnification, non-confocal fluorescence emission endoscopy apparatus and methods |
WO2009064753A1 (en) * | 2007-11-12 | 2009-05-22 | Cornell University | Non-imaging, weakly focused fluorescence emission apparatus and methods |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US9672471B2 (en) | 2007-12-18 | 2017-06-06 | Gearbox Llc | Systems, devices, and methods for detecting occlusions in a biological subject including spectral learning |
US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
US8280484B2 (en) | 2007-12-18 | 2012-10-02 | The Invention Science Fund I, Llc | System, devices, and methods for detecting occlusions in a biological subject |
DE202008009859U1 (en) * | 2007-12-21 | 2009-03-05 | Berthold Technologies Gmbh & Co. Kg | Device for the optional measurement of in particular luminescence and / or fluorescence radiation |
WO2009111542A2 (en) | 2008-03-04 | 2009-09-11 | Glucolight Corporation | Methods and systems for analyte level estimation in optical coherence tomography |
EP2278911A1 (en) | 2008-05-02 | 2011-02-02 | Masimo Corporation | Monitor configuration system |
JP2011519684A (en) | 2008-05-05 | 2011-07-14 | マシモ コーポレイション | Pulse oximeter system with electrical disconnect circuit |
US9042967B2 (en) | 2008-05-20 | 2015-05-26 | University Health Network | Device and method for wound imaging and monitoring |
USD621516S1 (en) | 2008-08-25 | 2010-08-10 | Masimo Laboratories, Inc. | Patient monitoring sensor |
EP2326239B1 (en) | 2008-07-03 | 2017-06-21 | Masimo Laboratories, Inc. | Protrusion for improving spectroscopic measurement of blood constituents |
US8512975B2 (en) * | 2008-07-24 | 2013-08-20 | Biomerieux, Inc. | Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements |
US8203438B2 (en) | 2008-07-29 | 2012-06-19 | Masimo Corporation | Alarm suspend system |
US8203704B2 (en) | 2008-08-04 | 2012-06-19 | Cercacor Laboratories, Inc. | Multi-stream sensor for noninvasive measurement of blood constituents |
WO2010031070A2 (en) | 2008-09-15 | 2010-03-18 | Masimo Corporation | Patient monitor including multi-parameter graphical display |
SE532941C2 (en) | 2008-09-15 | 2010-05-18 | Phasein Ab | Gas sampling line for breathing gases |
US8401602B2 (en) | 2008-10-13 | 2013-03-19 | Masimo Corporation | Secondary-emitter sensor position indicator |
US8346330B2 (en) | 2008-10-13 | 2013-01-01 | Masimo Corporation | Reflection-detector sensor position indicator |
US10167494B2 (en) * | 2008-10-31 | 2019-01-01 | Biomerieux, Inc. | Method for detection, characterization and/or identification of microorganisms in a sealed container |
US8771204B2 (en) | 2008-12-30 | 2014-07-08 | Masimo Corporation | Acoustic sensor assembly |
AU2010203674B2 (en) | 2009-01-09 | 2014-09-25 | Onpoint Technologies, Llc | Method and apparatus for monitoring combustion properties in an interior of a boiler |
US8588880B2 (en) | 2009-02-16 | 2013-11-19 | Masimo Corporation | Ear sensor |
US9323894B2 (en) | 2011-08-19 | 2016-04-26 | Masimo Corporation | Health care sanitation monitoring system |
US10007758B2 (en) | 2009-03-04 | 2018-06-26 | Masimo Corporation | Medical monitoring system |
EP3605550A1 (en) | 2009-03-04 | 2020-02-05 | Masimo Corporation | Medical monitoring system |
US10032002B2 (en) | 2009-03-04 | 2018-07-24 | Masimo Corporation | Medical monitoring system |
US8388353B2 (en) | 2009-03-11 | 2013-03-05 | Cercacor Laboratories, Inc. | Magnetic connector |
US20100234718A1 (en) * | 2009-03-12 | 2010-09-16 | Anand Sampath | Open architecture medical communication system |
US8897847B2 (en) | 2009-03-23 | 2014-11-25 | Masimo Corporation | Digit gauge for noninvasive optical sensor |
AU2010229864A1 (en) * | 2009-03-25 | 2011-10-27 | Los Alamos National Security, Llc | Rapid antemortem detection of infectious agents |
CN102362179A (en) | 2009-03-25 | 2012-02-22 | 洛斯阿拉莫斯国家安全有限责任公司 | Fiber optical assembly for fluorescence spectrometry |
US8989831B2 (en) | 2009-05-19 | 2015-03-24 | Masimo Corporation | Disposable components for reusable physiological sensor |
US8571619B2 (en) | 2009-05-20 | 2013-10-29 | Masimo Corporation | Hemoglobin display and patient treatment |
US8418524B2 (en) | 2009-06-12 | 2013-04-16 | Masimo Corporation | Non-invasive sensor calibration device |
US8670811B2 (en) | 2009-06-30 | 2014-03-11 | Masimo Corporation | Pulse oximetry system for adjusting medical ventilation |
US20110040197A1 (en) * | 2009-07-20 | 2011-02-17 | Masimo Corporation | Wireless patient monitoring system |
US20110208015A1 (en) * | 2009-07-20 | 2011-08-25 | Masimo Corporation | Wireless patient monitoring system |
US8471713B2 (en) | 2009-07-24 | 2013-06-25 | Cercacor Laboratories, Inc. | Interference detector for patient monitor |
US20110028806A1 (en) * | 2009-07-29 | 2011-02-03 | Sean Merritt | Reflectance calibration of fluorescence-based glucose measurements |
US8473020B2 (en) | 2009-07-29 | 2013-06-25 | Cercacor Laboratories, Inc. | Non-invasive physiological sensor cover |
US20110028809A1 (en) * | 2009-07-29 | 2011-02-03 | Masimo Corporation | Patient monitor ambient display device |
US20110087081A1 (en) * | 2009-08-03 | 2011-04-14 | Kiani Massi Joe E | Personalized physiological monitor |
US8688183B2 (en) | 2009-09-03 | 2014-04-01 | Ceracor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
JP2011053135A (en) * | 2009-09-03 | 2011-03-17 | Japan Aerospace Exploration Agency | Device and method for multi-wavelength fluorescence imaging for evaluation of biological metabolic function |
US20110172498A1 (en) | 2009-09-14 | 2011-07-14 | Olsen Gregory A | Spot check monitor credit system |
US9579039B2 (en) | 2011-01-10 | 2017-02-28 | Masimo Corporation | Non-invasive intravascular volume index monitor |
US20110137297A1 (en) | 2009-09-17 | 2011-06-09 | Kiani Massi Joe E | Pharmacological management system |
DE112010003689T5 (en) | 2009-09-17 | 2013-01-17 | Marcelo Lamego | Improved analyte monitoring using one or more accelerometers |
US8571618B1 (en) | 2009-09-28 | 2013-10-29 | Cercacor Laboratories, Inc. | Adaptive calibration system for spectrophotometric measurements |
US8401608B2 (en) * | 2009-09-30 | 2013-03-19 | Covidien Lp | Method of analyzing photon density waves in a medical monitor |
US20110082711A1 (en) | 2009-10-06 | 2011-04-07 | Masimo Laboratories, Inc. | Personal digital assistant or organizer for monitoring glucose levels |
US8715206B2 (en) | 2009-10-15 | 2014-05-06 | Masimo Corporation | Acoustic patient sensor |
US8821415B2 (en) | 2009-10-15 | 2014-09-02 | Masimo Corporation | Physiological acoustic monitoring system |
US8523781B2 (en) | 2009-10-15 | 2013-09-03 | Masimo Corporation | Bidirectional physiological information display |
US9066680B1 (en) | 2009-10-15 | 2015-06-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
WO2011047216A2 (en) | 2009-10-15 | 2011-04-21 | Masimo Corporation | Physiological acoustic monitoring system |
WO2011047211A1 (en) | 2009-10-15 | 2011-04-21 | Masimo Corporation | Pulse oximetry system with low noise cable hub |
US9848800B1 (en) | 2009-10-16 | 2017-12-26 | Masimo Corporation | Respiratory pause detector |
CA2781040A1 (en) * | 2009-11-17 | 2011-05-26 | Veralight, Inc. | Method and apparatus to detect coronary artery calcification or disease |
US9839381B1 (en) | 2009-11-24 | 2017-12-12 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
DE112010004682T5 (en) | 2009-12-04 | 2013-03-28 | Masimo Corporation | Calibration for multi-level physiological monitors |
US9153112B1 (en) | 2009-12-21 | 2015-10-06 | Masimo Corporation | Modular patient monitor |
GB2490817A (en) | 2010-01-19 | 2012-11-14 | Masimo Corp | Wellness analysis system |
GB2490832B (en) | 2010-03-01 | 2016-09-21 | Masimo Corp | Adaptive alarm system |
EP2544591B1 (en) | 2010-03-08 | 2021-07-21 | Masimo Corporation | Reprocessing of a physiological sensor |
JP2011185842A (en) | 2010-03-10 | 2011-09-22 | Fujifilm Corp | Method and device for analyzing low oxygen region of biosample by time resolving measurement of light induced self-fluorescence |
US9307928B1 (en) | 2010-03-30 | 2016-04-12 | Masimo Corporation | Plethysmographic respiration processor |
US8655807B2 (en) | 2010-04-05 | 2014-02-18 | Applied Research Associates, Inc. | Methods for forming recognition algorithms for laser-induced breakdown spectroscopy |
US9138180B1 (en) | 2010-05-03 | 2015-09-22 | Masimo Corporation | Sensor adapter cable |
US8712494B1 (en) | 2010-05-03 | 2014-04-29 | Masimo Corporation | Reflective non-invasive sensor |
US8666468B1 (en) | 2010-05-06 | 2014-03-04 | Masimo Corporation | Patient monitor for determining microcirculation state |
US9326712B1 (en) | 2010-06-02 | 2016-05-03 | Masimo Corporation | Opticoustic sensor |
US8740792B1 (en) | 2010-07-12 | 2014-06-03 | Masimo Corporation | Patient monitor capable of accounting for environmental conditions |
US9408542B1 (en) | 2010-07-22 | 2016-08-09 | Masimo Corporation | Non-invasive blood pressure measurement system |
WO2012027613A1 (en) | 2010-08-26 | 2012-03-01 | Masimo Corporation | Blood pressure measurement system |
JP5710767B2 (en) | 2010-09-28 | 2015-04-30 | マシモ コーポレイション | Depth of consciousness monitor including oximeter |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
US9995681B2 (en) * | 2010-09-28 | 2018-06-12 | Authentix, Inc. | Determining the quantity of a taggant in a liquid sample |
US9211095B1 (en) | 2010-10-13 | 2015-12-15 | Masimo Corporation | Physiological measurement logic engine |
US8723677B1 (en) | 2010-10-20 | 2014-05-13 | Masimo Corporation | Patient safety system with automatically adjusting bed |
EP2620093A1 (en) * | 2010-10-29 | 2013-07-31 | Olympus Corporation | Optical measurement device and probe |
US20120226117A1 (en) | 2010-12-01 | 2012-09-06 | Lamego Marcelo M | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US9877673B2 (en) | 2010-12-10 | 2018-01-30 | Clinitech, Llc | Transdermal sampling and analysis device |
US9451913B2 (en) | 2010-12-10 | 2016-09-27 | Touchtek Labs, Llc | Transdermal sampling and analysis device |
WO2012109671A1 (en) | 2011-02-13 | 2012-08-16 | Masimo Corporation | Medical characterization system |
US9066666B2 (en) | 2011-02-25 | 2015-06-30 | Cercacor Laboratories, Inc. | Patient monitor for monitoring microcirculation |
US8830449B1 (en) | 2011-04-18 | 2014-09-09 | Cercacor Laboratories, Inc. | Blood analysis system |
US9095316B2 (en) | 2011-04-20 | 2015-08-04 | Masimo Corporation | System for generating alarms based on alarm patterns |
US9622692B2 (en) | 2011-05-16 | 2017-04-18 | Masimo Corporation | Personal health device |
US9986919B2 (en) | 2011-06-21 | 2018-06-05 | Masimo Corporation | Patient monitoring system |
US9532722B2 (en) | 2011-06-21 | 2017-01-03 | Masimo Corporation | Patient monitoring system |
US9245668B1 (en) | 2011-06-29 | 2016-01-26 | Cercacor Laboratories, Inc. | Low noise cable providing communication between electronic sensor components and patient monitor |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US9192351B1 (en) | 2011-07-22 | 2015-11-24 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US8755872B1 (en) | 2011-07-28 | 2014-06-17 | Masimo Corporation | Patient monitoring system for indicating an abnormal condition |
US9782077B2 (en) | 2011-08-17 | 2017-10-10 | Masimo Corporation | Modulated physiological sensor |
KR20140102643A (en) | 2011-09-22 | 2014-08-22 | 더 조지 워싱턴 유니버시티 | Systems and methods for visualizing ablated tissue |
EP2757933B1 (en) | 2011-09-22 | 2019-02-06 | The George Washington University | Systems for visualizing ablated tissue |
EP2765909B1 (en) | 2011-10-13 | 2019-06-26 | Masimo Corporation | Physiological acoustic monitoring system |
EP3584799B1 (en) | 2011-10-13 | 2022-11-09 | Masimo Corporation | Medical monitoring hub |
US9943269B2 (en) | 2011-10-13 | 2018-04-17 | Masimo Corporation | System for displaying medical monitoring data |
US9808188B1 (en) | 2011-10-13 | 2017-11-07 | Masimo Corporation | Robust fractional saturation determination |
US9778079B1 (en) | 2011-10-27 | 2017-10-03 | Masimo Corporation | Physiological monitor gauge panel |
JP5970785B2 (en) * | 2011-11-16 | 2016-08-17 | ソニー株式会社 | Biological measuring device, biological measuring method, program, and recording medium |
US9968284B2 (en) | 2011-12-02 | 2018-05-15 | Clinitech, Llc | Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device |
US9445759B1 (en) | 2011-12-22 | 2016-09-20 | Cercacor Laboratories, Inc. | Blood glucose calibration system |
US9392945B2 (en) | 2012-01-04 | 2016-07-19 | Masimo Corporation | Automated CCHD screening and detection |
US11172890B2 (en) | 2012-01-04 | 2021-11-16 | Masimo Corporation | Automated condition screening and detection |
US10149616B2 (en) | 2012-02-09 | 2018-12-11 | Masimo Corporation | Wireless patient monitoring device |
US9480435B2 (en) | 2012-02-09 | 2016-11-01 | Masimo Corporation | Configurable patient monitoring system |
US10307111B2 (en) | 2012-02-09 | 2019-06-04 | Masimo Corporation | Patient position detection system |
US9195385B2 (en) | 2012-03-25 | 2015-11-24 | Masimo Corporation | Physiological monitor touchscreen interface |
US9131881B2 (en) | 2012-04-17 | 2015-09-15 | Masimo Corporation | Hypersaturation index |
ES2644601T3 (en) | 2012-04-19 | 2017-11-29 | Zolo Technologies, Inc. | Retroreflectors in the oven with the tunable diode laser absorption absorption spectrometer |
RU2511262C2 (en) * | 2012-05-29 | 2014-04-10 | Общество с ограниченной ответственностью "Научно-производственный центр медицинских и промышленных биотехнологий Спектролюкс" | Method for monitoring of treatment of disease involving fluorescence diagnostics of disease, and device for implementing it |
US10542903B2 (en) | 2012-06-07 | 2020-01-28 | Masimo Corporation | Depth of consciousness monitor |
US20160112684A1 (en) * | 2013-05-23 | 2016-04-21 | Medibotics Llc | Spectroscopic Finger Ring for Compositional Analysis of Food or Other Environmental Objects |
US9697928B2 (en) | 2012-08-01 | 2017-07-04 | Masimo Corporation | Automated assembly sensor cable |
US10827961B1 (en) | 2012-08-29 | 2020-11-10 | Masimo Corporation | Physiological measurement calibration |
US9955937B2 (en) | 2012-09-20 | 2018-05-01 | Masimo Corporation | Acoustic patient sensor coupler |
US9877650B2 (en) | 2012-09-20 | 2018-01-30 | Masimo Corporation | Physiological monitor with mobile computing device connectivity |
US9749232B2 (en) | 2012-09-20 | 2017-08-29 | Masimo Corporation | Intelligent medical network edge router |
US9717458B2 (en) | 2012-10-20 | 2017-08-01 | Masimo Corporation | Magnetic-flap optical sensor |
US9560996B2 (en) | 2012-10-30 | 2017-02-07 | Masimo Corporation | Universal medical system |
US9787568B2 (en) | 2012-11-05 | 2017-10-10 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9750461B1 (en) | 2013-01-02 | 2017-09-05 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US9724025B1 (en) | 2013-01-16 | 2017-08-08 | Masimo Corporation | Active-pulse blood analysis system |
US9750442B2 (en) | 2013-03-09 | 2017-09-05 | Masimo Corporation | Physiological status monitor |
US10441181B1 (en) | 2013-03-13 | 2019-10-15 | Masimo Corporation | Acoustic pulse and respiration monitoring system |
US9965946B2 (en) | 2013-03-13 | 2018-05-08 | Masimo Corporation | Systems and methods for monitoring a patient health network |
US9474474B2 (en) | 2013-03-14 | 2016-10-25 | Masimo Corporation | Patient monitor as a minimally invasive glucometer |
US9936917B2 (en) | 2013-03-14 | 2018-04-10 | Masimo Laboratories, Inc. | Patient monitor placement indicator |
US9986952B2 (en) | 2013-03-14 | 2018-06-05 | Masimo Corporation | Heart sound simulator |
US10004434B1 (en) | 2013-03-15 | 2018-06-26 | Georgetown University | Microfluidic systems for electrochemical transdermal analyte sensing using a capillary-located electrode |
US10456038B2 (en) | 2013-03-15 | 2019-10-29 | Cercacor Laboratories, Inc. | Cloud-based physiological monitoring system |
WO2014168734A1 (en) * | 2013-03-15 | 2014-10-16 | Cedars-Sinai Medical Center | Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof |
RU2539817C1 (en) * | 2013-07-16 | 2015-01-27 | Федеральное государственное бюджетное учреждение "Федеральный Центр сердца, крови и Эндокринологии имени В.А. Алмазова" Министерства здравоохранения Российской Федерации | Apparatus for fluorescent spectroscopy of biological tissue |
US9891079B2 (en) | 2013-07-17 | 2018-02-13 | Masimo Corporation | Pulser with double-bearing position encoder for non-invasive physiological monitoring |
US10555678B2 (en) | 2013-08-05 | 2020-02-11 | Masimo Corporation | Blood pressure monitor with valve-chamber assembly |
WO2015038683A2 (en) | 2013-09-12 | 2015-03-19 | Cercacor Laboratories, Inc. | Medical device management system |
WO2015054161A2 (en) | 2013-10-07 | 2015-04-16 | Masimo Corporation | Regional oximetry sensor |
US11147518B1 (en) | 2013-10-07 | 2021-10-19 | Masimo Corporation | Regional oximetry signal processor |
US10828007B1 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Acoustic sensor with attachment portion |
US10832818B2 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Alarm notification system |
JP2017500550A (en) | 2013-11-20 | 2017-01-05 | ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity | System and method for hyperspectral analysis of cardiac tissue |
US10279247B2 (en) | 2013-12-13 | 2019-05-07 | Masimo Corporation | Avatar-incentive healthcare therapy |
US11259745B2 (en) | 2014-01-28 | 2022-03-01 | Masimo Corporation | Autonomous drug delivery system |
US10086138B1 (en) | 2014-01-28 | 2018-10-02 | Masimo Corporation | Autonomous drug delivery system |
US10532174B2 (en) | 2014-02-21 | 2020-01-14 | Masimo Corporation | Assistive capnography device |
RU2551634C1 (en) * | 2014-04-28 | 2015-05-27 | Закрытое акционерное общество "Полупроводниковые приборы" | Device for fluorescent diagnostics of malignant neoplasms |
US9924897B1 (en) | 2014-06-12 | 2018-03-27 | Masimo Corporation | Heated reprocessing of physiological sensors |
US10123729B2 (en) | 2014-06-13 | 2018-11-13 | Nanthealth, Inc. | Alarm fatigue management systems and methods |
US10231670B2 (en) | 2014-06-19 | 2019-03-19 | Masimo Corporation | Proximity sensor in pulse oximeter |
CN115989999A (en) | 2014-07-24 | 2023-04-21 | 大学健康网络 | Collection and analysis of data for diagnostic purposes |
US10111591B2 (en) | 2014-08-26 | 2018-10-30 | Nanthealth, Inc. | Real-time monitoring systems and methods in a healthcare environment |
WO2016036985A1 (en) | 2014-09-04 | 2016-03-10 | Masimo Corportion | Total hemoglobin index system |
US10383520B2 (en) | 2014-09-18 | 2019-08-20 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
WO2016057553A1 (en) | 2014-10-07 | 2016-04-14 | Masimo Corporation | Modular physiological sensors |
WO2016073476A1 (en) | 2014-11-03 | 2016-05-12 | The George Washington University | Systems and methods for lesion assessment |
CN107427213B (en) | 2014-11-03 | 2021-04-16 | 460医学股份有限公司 | System and method for evaluation of contact quality |
CN104483299A (en) * | 2014-12-10 | 2015-04-01 | 安徽理工大学 | Method for identifying water hazard water source of mining area |
WO2016118922A1 (en) | 2015-01-23 | 2016-07-28 | Masimo Sweden Ab | Nasal/oral cannula system and manufacturing |
US10568553B2 (en) | 2015-02-06 | 2020-02-25 | Masimo Corporation | Soft boot pulse oximetry sensor |
USD755392S1 (en) | 2015-02-06 | 2016-05-03 | Masimo Corporation | Pulse oximetry sensor |
EP3254339A1 (en) | 2015-02-06 | 2017-12-13 | Masimo Corporation | Connector assembly with pogo pins for use with medical sensors |
CA2974830C (en) | 2015-02-06 | 2023-06-27 | Masimo Corporation | Fold flex circuit for lnop |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
WO2016191307A1 (en) | 2015-05-22 | 2016-12-01 | Cercacor Laboratories, Inc. | Non-invasive optical physiological differential pathlength sensor |
US10448871B2 (en) | 2015-07-02 | 2019-10-22 | Masimo Corporation | Advanced pulse oximetry sensor |
US10779904B2 (en) | 2015-07-19 | 2020-09-22 | 460Medical, Inc. | Systems and methods for lesion formation and assessment |
WO2017023931A1 (en) | 2015-08-03 | 2017-02-09 | Georgetown University | Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process |
US11656180B2 (en) | 2015-08-03 | 2023-05-23 | Ysi, Inc. | Multi excitation-multi emission fluorometer for multiparameter water quality monitoring |
CN108351300A (en) * | 2015-08-03 | 2018-07-31 | Ysi公司 | More excitations-multi-emitting fluorimeter for multi-parameter water quality monitoring |
JP6855443B2 (en) | 2015-08-11 | 2021-04-07 | マシモ・コーポレイション | Medical monitoring analysis and regeneration including identification marks that respond to light reduced by body tissue |
US10226187B2 (en) | 2015-08-31 | 2019-03-12 | Masimo Corporation | Patient-worn wireless physiological sensor |
US11504066B1 (en) | 2015-09-04 | 2022-11-22 | Cercacor Laboratories, Inc. | Low-noise sensor system |
US11679579B2 (en) | 2015-12-17 | 2023-06-20 | Masimo Corporation | Varnish-coated release liner |
US10799129B2 (en) * | 2016-01-07 | 2020-10-13 | Panasonic Intellectual Property Management Co., Ltd. | Biological information measuring device including light source, light detector, and control circuit |
US10537285B2 (en) | 2016-03-04 | 2020-01-21 | Masimo Corporation | Nose sensor |
US10993662B2 (en) | 2016-03-04 | 2021-05-04 | Masimo Corporation | Nose sensor |
US10656089B2 (en) | 2016-04-01 | 2020-05-19 | Black Light Surgical, Inc. | Systems, devices, and methods for time-resolved fluorescent spectroscopy |
US11191484B2 (en) | 2016-04-29 | 2021-12-07 | Masimo Corporation | Optical sensor tape |
WO2018009612A1 (en) | 2016-07-06 | 2018-01-11 | Patient Doctor Technologies, Inc. | Secure and zero knowledge data sharing for cloud applications |
US10617302B2 (en) | 2016-07-07 | 2020-04-14 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
JP7197473B2 (en) | 2016-10-13 | 2022-12-27 | マシモ・コーポレイション | System and method for patient fall detection |
US11504058B1 (en) | 2016-12-02 | 2022-11-22 | Masimo Corporation | Multi-site noninvasive measurement of a physiological parameter |
WO2018119239A1 (en) | 2016-12-22 | 2018-06-28 | Cercacor Laboratories, Inc | Methods and devices for detecting intensity of light with translucent detector |
US10721785B2 (en) | 2017-01-18 | 2020-07-21 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
WO2018156804A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | System for displaying medical monitoring data |
US10388120B2 (en) | 2017-02-24 | 2019-08-20 | Masimo Corporation | Localized projection of audible noises in medical settings |
WO2018156648A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | Managing dynamic licenses for physiological parameters in a patient monitoring environment |
US11086609B2 (en) | 2017-02-24 | 2021-08-10 | Masimo Corporation | Medical monitoring hub |
US10327713B2 (en) | 2017-02-24 | 2019-06-25 | Masimo Corporation | Modular multi-parameter patient monitoring device |
WO2018156809A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | Augmented reality system for displaying patient data |
EP3592231A1 (en) | 2017-03-10 | 2020-01-15 | Masimo Corporation | Pneumonia screener |
WO2018194992A1 (en) | 2017-04-18 | 2018-10-25 | Masimo Corporation | Nose sensor |
US10918281B2 (en) | 2017-04-26 | 2021-02-16 | Masimo Corporation | Medical monitoring device having multiple configurations |
JP7278220B2 (en) | 2017-04-28 | 2023-05-19 | マシモ・コーポレイション | Spot check measurement system |
USD835285S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835284S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835283S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835282S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
EP3622529A1 (en) | 2017-05-08 | 2020-03-18 | Masimo Corporation | System for pairing a medical system to a network controller by use of a dongle |
WO2019014629A1 (en) | 2017-07-13 | 2019-01-17 | Cercacor Laboratories, Inc. | Medical monitoring device for harmonizing physiological measurements |
USD906970S1 (en) | 2017-08-15 | 2021-01-05 | Masimo Corporation | Connector |
USD890708S1 (en) | 2017-08-15 | 2020-07-21 | Masimo Corporation | Connector |
US10637181B2 (en) | 2017-08-15 | 2020-04-28 | Masimo Corporation | Water resistant connector for noninvasive patient monitor |
WO2019079643A1 (en) | 2017-10-19 | 2019-04-25 | Masimo Corporation | Display arrangement for medical monitoring system |
JP2019078715A (en) * | 2017-10-27 | 2019-05-23 | セイコーエプソン株式会社 | Spectrometry device and method for spectrometry |
WO2019089655A1 (en) | 2017-10-31 | 2019-05-09 | Masimo Corporation | System for displaying oxygen state indications |
USD925597S1 (en) | 2017-10-31 | 2021-07-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
US11766198B2 (en) | 2018-02-02 | 2023-09-26 | Cercacor Laboratories, Inc. | Limb-worn patient monitoring device |
US10952616B2 (en) | 2018-03-30 | 2021-03-23 | Canon U.S.A., Inc. | Fluorescence imaging apparatus |
WO2019204368A1 (en) | 2018-04-19 | 2019-10-24 | Masimo Corporation | Mobile patient alarm display |
WO2019209915A1 (en) | 2018-04-24 | 2019-10-31 | Cercacor Laboratories, Inc. | Easy insert finger sensor for transmission based spectroscopy sensor |
CN112512406A (en) | 2018-06-06 | 2021-03-16 | 梅西莫股份有限公司 | Opioid overdose monitoring |
US10779098B2 (en) | 2018-07-10 | 2020-09-15 | Masimo Corporation | Patient monitor alarm speaker analyzer |
US11872156B2 (en) | 2018-08-22 | 2024-01-16 | Masimo Corporation | Core body temperature measurement |
US10743749B2 (en) | 2018-09-14 | 2020-08-18 | Canon U.S.A., Inc. | System and method for detecting optical probe connection |
USD999246S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
CN112997366A (en) | 2018-10-11 | 2021-06-18 | 迈心诺公司 | Patient connector assembly with vertical detent |
USD998631S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917564S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD916135S1 (en) | 2018-10-11 | 2021-04-13 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917550S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
US11389093B2 (en) | 2018-10-11 | 2022-07-19 | Masimo Corporation | Low noise oximetry cable |
US11406286B2 (en) | 2018-10-11 | 2022-08-09 | Masimo Corporation | Patient monitoring device with improved user interface |
USD998630S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
AU2019357721A1 (en) | 2018-10-12 | 2021-05-27 | Masimo Corporation | System for transmission of sensor data using dual communication protocol |
US11464410B2 (en) | 2018-10-12 | 2022-10-11 | Masimo Corporation | Medical systems and methods |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
US11684296B2 (en) | 2018-12-21 | 2023-06-27 | Cercacor Laboratories, Inc. | Noninvasive physiological sensor |
US11633129B2 (en) | 2019-04-05 | 2023-04-25 | Cambridge Medical Technologies LLC | Non-invasive transdermal sampling and analysis device incorporating redox cofactors |
AU2020259445A1 (en) | 2019-04-17 | 2021-12-02 | Masimo Corporation | Patient monitoring systems, devices, and methods |
US11375931B2 (en) | 2019-08-08 | 2022-07-05 | Cambridge Medical Technologies LLC | Non-invasive transdermal sampling and analysis device incorporating an electrochemical bioassay |
USD921202S1 (en) | 2019-08-16 | 2021-06-01 | Masimo Corporation | Holder for a blood pressure device |
USD919094S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Blood pressure device |
USD985498S1 (en) | 2019-08-16 | 2023-05-09 | Masimo Corporation | Connector |
USD917704S1 (en) | 2019-08-16 | 2021-04-27 | Masimo Corporation | Patient monitor |
USD919100S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Holder for a patient monitor |
US11832940B2 (en) | 2019-08-27 | 2023-12-05 | Cercacor Laboratories, Inc. | Non-invasive medical monitoring device for blood analyte measurements |
USD927699S1 (en) | 2019-10-18 | 2021-08-10 | Masimo Corporation | Electrode pad |
WO2021077019A1 (en) | 2019-10-18 | 2021-04-22 | Masimo Corporation | Display layout and interactive objects for patient monitoring |
WO2021163447A1 (en) | 2020-02-13 | 2021-08-19 | Masimo Corporation | System and method for monitoring clinical activities |
US11879960B2 (en) | 2020-02-13 | 2024-01-23 | Masimo Corporation | System and method for monitoring clinical activities |
US20210290177A1 (en) | 2020-03-20 | 2021-09-23 | Masimo Corporation | Wearable device for monitoring health status |
USD933232S1 (en) | 2020-05-11 | 2021-10-12 | Masimo Corporation | Blood pressure monitor |
USD979516S1 (en) | 2020-05-11 | 2023-02-28 | Masimo Corporation | Connector |
USD980091S1 (en) | 2020-07-27 | 2023-03-07 | Masimo Corporation | Wearable temperature measurement device |
USD974193S1 (en) | 2020-07-27 | 2023-01-03 | Masimo Corporation | Wearable temperature measurement device |
US10952655B1 (en) * | 2020-09-21 | 2021-03-23 | The Florida International University Board Of Trustees | Retinal blood vessel oximetry using retinal auofluorescence |
USD946598S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD946596S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD946597S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD997365S1 (en) | 2021-06-24 | 2023-08-29 | Masimo Corporation | Physiological nose sensor |
USD1000975S1 (en) | 2021-09-22 | 2023-10-10 | Masimo Corporation | Wearable temperature measurement device |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012223A1 (en) * | 1988-06-08 | 1989-12-14 | Barbour Randall L | A method of imaging a random medium |
US5122974A (en) * | 1989-02-06 | 1992-06-16 | Nim, Inc. | Phase modulated spectrophotometry |
EP0703445A2 (en) * | 1994-09-22 | 1996-03-27 | Hamamatsu Photonics K.K. | Method and apparatus for measuring concentration of absorptive constituent in scattering medium |
WO1997008538A1 (en) * | 1995-08-24 | 1997-03-06 | Purdue Research Foundation | Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE23752T1 (en) * | 1980-08-21 | 1986-12-15 | Oriel Scient Ltd | OPTICAL ANALYZER. |
US4569354A (en) * | 1982-03-22 | 1986-02-11 | Boston University | Method and apparatus for measuring natural retinal fluorescence |
JPS60209146A (en) * | 1984-03-31 | 1985-10-21 | Olympus Optical Co Ltd | Fluorescence spectrochemical analysis device |
SE455646B (en) * | 1984-10-22 | 1988-07-25 | Radians Innova Ab | FLUORESCENT DEVICE |
DE3535652A1 (en) * | 1984-11-01 | 1986-04-30 | Jenoptik Jena Gmbh, Ddr 6900 Jena | ARRANGEMENT FOR OPTICAL RADIATION IN PHOTOMETRIC ANALYZER MEASURING DEVICES |
US4641650A (en) * | 1985-03-11 | 1987-02-10 | Mcm Laboratories, Inc. | Probe-and-fire lasers |
CN85100424B (en) * | 1985-04-01 | 1986-10-29 | 上海医疗器械研究所 | Natural fluorscence diagnosis instrument used for diagnosising malignant tumour |
US4945245A (en) * | 1986-01-14 | 1990-07-31 | Levin Herman W | Evanescent wave background fluorescence/absorbance detection |
US4996421A (en) * | 1988-10-31 | 1991-02-26 | Amoco Corporation | Method an system of geophysical exploration |
US5419323A (en) * | 1988-12-21 | 1995-05-30 | Massachusetts Institute Of Technology | Method for laser induced fluorescence of tissue |
US5187672A (en) * | 1989-02-06 | 1993-02-16 | Nim Incorporated | Phase modulation spectroscopic system |
CA2042075C (en) * | 1991-05-08 | 2001-01-23 | Branko Palcic | Endoscopic imaging system |
US5635402A (en) * | 1992-03-05 | 1997-06-03 | Alfano; Robert R. | Technique for determining whether a cell is malignant as opposed to non-malignant using extrinsic fluorescence spectroscopy |
US5452723A (en) * | 1992-07-24 | 1995-09-26 | Massachusetts Institute Of Technology | Calibrated spectrographic imaging |
US5341805A (en) * | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
US5349954A (en) * | 1993-07-23 | 1994-09-27 | General Electric Company | Tumor tissue characterization apparatus and method |
US5456252A (en) * | 1993-09-30 | 1995-10-10 | Cedars-Sinai Medical Center | Induced fluorescence spectroscopy blood perfusion and pH monitor and method |
US5515864A (en) * | 1994-04-21 | 1996-05-14 | Zuckerman; Ralph | Method and apparatus for the in vivo measurement of oxygen concentration levels by the indirect determination of fluoescence lifetime |
US5760406A (en) * | 1996-06-03 | 1998-06-02 | Powers; Linda | Method and apparatus for sensing the presence of microbes |
US6124597A (en) | 1997-07-07 | 2000-09-26 | Cedars-Sinai Medical Center | Method and devices for laser induced fluorescence attenuation spectroscopy |
US6219575B1 (en) * | 1998-10-23 | 2001-04-17 | Babak Nemati | Method and apparatus to enhance optical transparency of biological tissues |
-
1997
- 1997-07-07 US US08/889,017 patent/US6124597A/en not_active Expired - Lifetime
-
1998
- 1998-06-09 EP EP05007322A patent/EP1562038A3/en not_active Withdrawn
- 1998-06-09 EP EP98926475A patent/EP0995095B1/en not_active Expired - Lifetime
- 1998-06-09 DE DE69829664T patent/DE69829664D1/en not_active Expired - Lifetime
- 1998-06-09 WO PCT/US1998/011937 patent/WO1999002956A2/en active IP Right Grant
- 1998-06-09 JP JP2000502389A patent/JP2001509589A/en active Pending
- 1998-06-09 AU AU78306/98A patent/AU752061B2/en not_active Ceased
-
2000
- 2000-06-28 US US09/605,176 patent/US6697657B1/en not_active Expired - Fee Related
-
2002
- 2002-01-23 US US10/056,335 patent/USRE39672E1/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012223A1 (en) * | 1988-06-08 | 1989-12-14 | Barbour Randall L | A method of imaging a random medium |
US5122974A (en) * | 1989-02-06 | 1992-06-16 | Nim, Inc. | Phase modulated spectrophotometry |
EP0703445A2 (en) * | 1994-09-22 | 1996-03-27 | Hamamatsu Photonics K.K. | Method and apparatus for measuring concentration of absorptive constituent in scattering medium |
WO1997008538A1 (en) * | 1995-08-24 | 1997-03-06 | Purdue Research Foundation | Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39672E1 (en) | 1997-07-07 | 2007-06-05 | Cedars-Sinai Medical Center | Method and devices for laser induced fluorescence attenuation spectroscopy |
US6587702B1 (en) | 1999-01-22 | 2003-07-01 | Instrumentation Metrics, Inc | Classification and characterization of tissue through features related to adipose tissue |
WO2001052725A1 (en) * | 2000-01-21 | 2001-07-26 | Instrumentation Metrics, Inc. | Classification and characterization of tissue through features related to adipose tissue |
WO2001060246A2 (en) * | 2000-02-18 | 2001-08-23 | Argose, Inc. | Multivariate analysis of green to ultraviolet spectra of cell and tissue samples |
WO2001060246A3 (en) * | 2000-02-18 | 2002-02-28 | Argose Inc | Multivariate analysis of green to ultraviolet spectra of cell and tissue samples |
JP4954418B2 (en) * | 2000-03-31 | 2012-06-13 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus for locating anomalous regions in turbid media |
US6377841B1 (en) | 2000-03-31 | 2002-04-23 | Vanderbilt University | Tumor demarcation using optical spectroscopy |
JP2003528678A (en) * | 2000-03-31 | 2003-09-30 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus for localizing anomalous regions in a turbid medium |
WO2002024048A2 (en) | 2000-09-25 | 2002-03-28 | Vital Medical Ltd. | Apparatus and method for monitoring tissue vitality parameters |
WO2002024048A3 (en) * | 2000-09-25 | 2002-07-18 | Vital Medical Ltd | Apparatus and method for monitoring tissue vitality parameters |
US7130672B2 (en) | 2000-09-25 | 2006-10-31 | Critisense Ltd. | Apparatus and method for monitoring tissue vitality parameters |
US7313424B2 (en) | 2002-03-20 | 2007-12-25 | Critisense Ltd. | Diagnosis of body metabolic emergency state |
WO2004039254A1 (en) * | 2002-10-31 | 2004-05-13 | Shanghai Shengbiao Science And Technology Co., Ltd. | A laser-induced fluorescence method for precancerous lesion diagnosis and an endoscope precancerous lesion diagnosis apparatus thereof |
US7558609B2 (en) | 2004-04-06 | 2009-07-07 | National University Corporation Okayama University | Cerebral-ischemia supervisory monitor |
JP2016540558A (en) * | 2013-11-14 | 2016-12-28 | ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity | System and method for determining the depth of damage using fluorescence imaging |
WO2016166067A1 (en) * | 2015-04-17 | 2016-10-20 | Koninklijke Philips N.V. | Detection of anisotropic biological tissue |
CN107529992A (en) * | 2015-04-17 | 2018-01-02 | 皇家飞利浦有限公司 | The detection of anisotropic biological tissue |
US11202606B2 (en) | 2015-04-17 | 2021-12-21 | Koninklijke Philips N.V. | Detection of anisotropic biological tissue |
CN109270044A (en) * | 2018-11-28 | 2019-01-25 | 安徽理工大学 | A kind of laser induced fluorescence vegetable oil doping strong tea water identification method |
Also Published As
Publication number | Publication date |
---|---|
EP1562038A3 (en) | 2005-11-23 |
US6124597A (en) | 2000-09-26 |
AU7830698A (en) | 1999-02-08 |
DE69829664D1 (en) | 2005-05-12 |
EP0995095B1 (en) | 2005-04-06 |
USRE39672E1 (en) | 2007-06-05 |
EP1562038A2 (en) | 2005-08-10 |
WO1999002956A3 (en) | 1999-04-29 |
US6697657B1 (en) | 2004-02-24 |
AU752061B2 (en) | 2002-09-05 |
JP2001509589A (en) | 2001-07-24 |
EP0995095A2 (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6124597A (en) | Method and devices for laser induced fluorescence attenuation spectroscopy | |
Ge et al. | Identification of colonic dysplasia and neoplasia by diffuse reflectance spectroscopy and pattern recognition techniques | |
US8532726B2 (en) | Invasive chemometry | |
US7330746B2 (en) | Non-invasive biochemical analysis | |
EP2198268B1 (en) | Optical apparatus for determining a blood characteristic | |
US5421337A (en) | Spectral diagnosis of diseased tissue | |
JP5982364B2 (en) | Apparatus and method for identifying and monitoring components or characteristics of a measurement medium, in particular physiological blood values | |
JP3875798B2 (en) | Method of operating a bloodless measuring device for blood component concentration and bloodless measuring device | |
US6002953A (en) | Non-invasive IR transmission measurement of analyte in the tympanic membrane | |
US11147482B2 (en) | Method and system for non-invasive blood glucose measurement using signal change of the non-glucose components induced by the presence of glucose | |
US5876121A (en) | Substrate temperature measurement by infrared spectroscopy | |
US7961305B2 (en) | Optical device components | |
US6088087A (en) | Transcutaneous measurement of substance in body tissues or fluid | |
US20080200780A1 (en) | Optical measurement of cellular energetics | |
JPH11510254A (en) | Optical microprobe and method for spectral analysis of materials | |
US20230148312A1 (en) | Device for non-invasive blood glucose concentration measurement | |
CN112244822A (en) | Tissue oxygen metabolism rate detection device and method based on near-infrared broadband spectrum | |
KR100883153B1 (en) | Instrument for noninvasively measuring blood sugar level | |
KR100300960B1 (en) | Method and device for noninvasive determination of the concentrations of blood components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998926475 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 78306/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998926475 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 78306/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998926475 Country of ref document: EP |